The ASCEND  Study  
P500 -0118, Rev. 8.0, 04  APR 2019   CONFIDENTIAL  
The ASCEND  Study 
A Clinical Evaluation of the UP Drug-Coated 
Device in Patients with Chronic Rhinosinusitis 
Signature Page 
Approved by:  
James W. Stambaugh  
Senior Vice President Clinical and Medical Affairs  Date  
Sarabjyot ( Sara) Mankoo  
Associate Director o f Regulatory Affairs  Date  
Boris Karanfilov , MD  
Principal Investigator  Date  04/08/2019 23:00:20 UTC
SignNow e-signature ID: 28bc1553a9...
04/06/2019 01:08:49 UTC
SignNow e-signature ID: 1f93a35411...
04/05/2019 23:13:25 UTCSignNow e-signature ID: fba6c19b93...04/08/201904/05/2019
April 5, 2019
SignNow E-Signature Audit Log
Document name: ASCEND_Protocol_Version 8.0_04Apr2019 Signature page
Document ID: 8d8604d6fbb792cfeb9e1123348aabf8d9093543
Document page count: 1
Client Event By Server Time Client Time IP Address
SignNow Web Application Uploaded Document araman@intersectent.com 2019-04-05 03:31:44 am UTC 2019-04-05 03:31:43 am UTC 67.164.2.16
SignNow Web Application Viewed the Document araman@intersectent.com 2019-04-05 03:31:52 am UTC 2019-04-05 03:31:52 am UTC 67.164.2.16
SignNow Web Application Document Saved araman@intersectent.com 2019-04-05 03:38:48 am UTC 2019-04-05 03:38:47 am UTC 67.164.2.16
iPhone Application 2 Document Downloaded ohiosinus@gmail.com 2019-04-05 11:12:44 pm UTC 75.188.143.2
SignNow Web Application Viewed the Document ohiosinus@gmail.com 2019-04-05 11:12:45 pm UTC 2019-04-05 11:12:45 pm UTC 75.188.143.2
SignNow Web ApplicationSigned the Document, Signature ID:
fba6c19b9308e48b6304ohiosinus@gmail.com 2019-04-05 11:13:25 pm UTC 2019-04-05 11:13:02 pm UTC 75.188.143.2
SignNow Web Application Added a Text ohiosinus@gmail.com 2019-04-05 11:13:25 pm UTC 2019-04-05 11:13:09 pm UTC 75.188.143.2
iPhone Application 2 Document Saved ohiosinus@gmail.com 2019-04-05 11:13:29 pm UTC 2019-04-05 11:13:23 pm UTC 75.188.143.2
iPhone Application 2 Document Downloaded ohiosinus@gmail.com 2019-04-05 11:13:36 pm UTC 75.188.143.2
SignNow Web Application Viewed the Document jstambaugh@intersectent.com 2019-04-06 01:08:31 am UTC 2019-04-06 01:08:31 am UTC 98.207.32.65
SignNow Web Application Added a Text jstambaugh@intersectent.com 2019-04-06 01:08:49 am UTC 2019-04-06 01:08:47 am UTC 98.207.32.65
SignNow Web ApplicationSigned the Document, Signature ID:
1f93a354115d427e8e12jstambaugh@intersectent.com 2019-04-06 01:08:49 am UTC 2019-04-06 01:08:47 am UTC 98.207.32.65
SignNow Web Application Document Saved jstambaugh@intersectent.com 2019-04-06 01:08:51 am UTC 2019-04-06 01:08:47 am UTC 98.207.32.65
SignNow Web Application Viewed the Document smankoo@intersectent.com 2019-04-08 07:40:29 pm UTC 2019-04-08 07:40:29 pm UTC 12.94.93.214
SignNow Web Application Document Downloaded smankoo@intersectent.com 2019-04-08 07:40:36 pm UTC 2019-04-08 07:40:33 pm UTC 12.94.93.214
SignNow Web Application Document Downloaded smankoo@intersectent.com 2019-04-08 07:40:40 pm UTC 2019-04-08 07:40:38 pm UTC 12.94.93.214
SignNow Web Application Added a Text smankoo@intersectent.com 2019-04-08 11:00:20 pm UTC 2019-04-08 11:00:19 pm UTC 12.94.93.214
SignNow Web ApplicationSigned the Document, Signature ID:
28bc1553a9931d5f873esmankoo@intersectent.com 2019-04-08 11:00:20 pm UTC 2019-04-08 11:00:19 pm UTC 12.94.93.214
SignNow Web Application Document Saved smankoo@intersectent.com 2019-04-08 11:00:36 pm UTC 2019-04-08 11:00:19 pm UTC 12.94.93.214
SignNow Web Application Viewed the Document araman@intersectent.com 2019-04-08 11:10:53 pm UTC 2019-04-08 11:10:53 pm UTC 12.94.93.214
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  1 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
CLINICAL STUDY PROTOCOL  
1 TITLE PAGE 
Study  Title  The ASCEND Study: A Clinical Evaluation of the UP  Drug -Coated  
Device in Patients with Chronic Rhinosinusitis  
Protocol Number  P500- 0118 
Investigational Device  UP Drug -Coated  Device (mometasone furoate, 3000 mcg)  
Study Design  Prospective, multicenter, clinical trial, enrolling patients into two 
consecutive cohorts : a PK cohort  and a randomized, blinded, intra -
patient control led cohort  
Sponsor’s Name and 
Address  Intersect ENT, Inc.  
1555 Adams Drive  
Menlo Park, CA 94025 USA 
Tel:  +1 650- 641-2100  
Fax: +1 650- 641-2053  
National Principal 
Investigator  Boris Karanfilov , MD  
Director, The Ohio Sinus Institute  
5378 Avery Road 
Dublin, OH 43016 USA  
 
Name and address of each participating clinical investigator will be 
maintained on file by Intersect ENT  
Data Management and 
Study Monitoring  Intersect ENT , Inc. 
Biostatistics and Data Analysis  Intersect ENT, Inc.  
This study will be conducted under the guidance of the International Council on Harmonisation (ICH) Good 
Clinical Practice, Clinical investigation of medical devices for human subjects -  Good clinical practice (BS EN 
ISO 14155) and other applicable local a nd federal regulations, including the archiving of essential documents.  
 
 
 
 
 
 
 
 
  
 
CONFIDENTIALITY STATEMENT  
This document is the property of Intersect ENT , Inc. The document is highly confidential and is to be used only 
in connection with matters authorized by a senior representative of Intersect ENT, and no part of it is to be 
disclosed to a third party without prior written permission from Intersect ENT.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  2 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Revision History:  
Revi sion Revision  Date  Summary of Changes  
1.0 15 Feb 2018  Initial release  
2.0 23 Mar 2018  • Renamed pilot to R andomized cohort  
• Increased sample size of R andomized cohort to 70 subjects 
and 10 study centers  
• Added language to allow dilation of the maxillary or sphenoid 
sinus with the same Sinus Dilation Device after successful 
dilation of both frontal sinuses, if necessary  
• Updated sample size justification, analysis of the primary 
efficacy endpoint, analysis of secondary endpoints, and 
sensitivity analysis for the primary efficacy endpoint  
• Added definitions  of safety, intent -to-treat, and per -treatment -
evaluable populations  
• Added inclusion criteria to confirm bilateral obstruction of the FSO on endoscopy at baseline  
• Updated list of compatible devices  
• Several editorial changes for consistency throughout the 
protocol  
3.0 05 Apr 2018 • Corrected error in the flow diagram – number of subjects 
changed from N=50 to N=70; pilot cohort corrected to randomized cohort  
•  Removed 'stenosed' in the study objective and design sections  
4.0 26 Apr 2018  • Increased the number of enrolling sites for the PK cohort to up 
to 3 study centers  and indicated PK enrollment first  
• Updated study population to include only patients who had 
prior endoscopic sinus surgery (> 30 days with a healed 
mucosa), including ethmoidectomy and uncinectomy 
• Edited inclusionary criteria to disallow any additional surgical 
interventions at the baseline balloon dilation procedure  
• Edited exclusionary criteria to disallow patients with cystic fibrosis  
• Included assessment of urinary cortisol over 24 hours at 
baseline (pre- procedure) a nd 24 hours after the baseline 
procedure (post -procedure) towards additional safety 
assessment in the PK cohort  
• Included descriptive statistics for analysis of safety measures  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  3 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Updated concomitant medications in the synopsis to match the 
body of the protocol  
• Updated flow diagram and schedule of assessments table for 
PK cohort to include urine analysis at baseline and Day 1 post -
procedure ; separate d screening and baseline visits  
• Deleted reference to investigator brochure for site training 
(Section 17.2.1)  
5.0  21 June 2018  • Added D ay 60 follow -up visit to the Randomized cohort  and 
updated relevant sections throughout the protocol to include 
Day 60 visit   
• Updated Day 30 visit window from ± 3 days to ± 2 days in the 
Randomized cohort  
• Modifi ed inclusionary criteria to allow  CT scan  confirming 
bilateral frontal disease within 30 days prior to randomization 
in the Randomized cohort  instead of 30 days prior to 
enrollment  
• Updated compatible accessory devices and baseline procedure steps to include a n optional  use of sinus g uide c atheter handle  
• Updated baseline procedure steps to align with the IFU  
• Removed IFU as an appendix to the ASCEND protocol  
• Updated reference to “guidewire” to “lightwire” throughout protocol  
• Updat ed baseline procedure  descrip tion to allow for  dilation of 
the maxillary and/or sphenoid sinus , if clinical necessary  in the 
Randomized cohort , with a commercially available b alloon 
sinuplasty device prior to randomization  
6.0 22 October 2018  • Updated the name of the investigational device to UP Drug -
Coated Device and the name of the control device to the ‘UP 
Control Device’  
• Changed the timepoint of  the primary efficacy endpoi nt in the 
randomized cohort from Day 30 to Day 14 
• Added video- endoscopy grading by an independent reviewer 
at Day 14  
• Updated exclusion criteria (a) to exclude patients wi th ethmoid 
polyposis of grade ≥ 2  
• Removed the assessment of estimated FSO diameter post -
dilation following the baseline procedure   
• Added a 14- day r estriction for use of oral steroids, budesonide 
or other steroid irrigations/rinses or drops, and nebulized 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  4 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
steroids administered nasally, prior to the baseline procedure  
in the randomized cohort  
• Updated  required use of saline sprays/rinses/irrigations starting 
on Day 2 in all subjects in the randomized cohort  
• Updated allowance of intranasal corticosteroid sprays  after 
Day 14 if medically necessary in the randomized cohort  
• Updated Day 60 visit window from ± 3 days to ± 7 days in the 
randomized cohort  
• Modified inclusion criteria (f) to allow dilation of the 
maxillary and/or sphenoid sinus with a commercially available 
sinus dilation device, if clinically necessary, prior to randomization in the randomized cohort.  
• Modified inclusion criteria  (k) to include optional use of a 
frontal sinus seeker to assess feasibility of balloon dilation of the FSO  
• Added a section to describe the personnel and measures to 
achieve blinding in the randomized cohort  
• Increased the number of enrolling sites for the randomized cohort to up to 12 study centers  
7.0 12 November 2018 • Changed the timepoint of the primary efficacy endpoint in the randomized cohort from Day 14 to Day 30 
• Added definition of acute rhinosinusitis to Section 3: 
Definition of terms  
• Clarified the  use of corticosteroid -eluting implants (including  
PROPEL
®, PROPEL® Mini, PROPEL® Contour and 
SINUVA® Sinus Implant) is prohibited 14 days prior to 
baseline  
8.0 04 April  2019  • Increased the number of enrolling sit es for the randomized 
cohort to include up to 15 study centers  
• Modified inclusion criterion (k) to confirm access of each FSO 
with a light- assisted or image -guided instrument such as a 
frontal sinus seeker  
• Modified exclusion  criterion  (p) to disallow patient s who have 
glaucoma with intraocular pressure > 21 mm Hg even with 
pressure lowering medication  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  5 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
TABLE OF CONTENTS  
1 TITLE PAGE ................................................................................................................................. 1 
2 LIST OF ABBREVIATION S ....................................................................................................... 7 
3 DEFINITIONS OF TERMS  ......................................................................................................... 8 
4 PROTOCOL SUMMARY .......................................................................................................... 12 
5 STUDY FLOW DIAGRAM  ........................................................................................................ 17 
6 SCHEDULE OF ASSESSME NTS  ............................................................................................. 18 
6.1 PK Cohort  ......................................................................................................................... 18 
6.2 Randomized Cohort  .......................................................................................................... 19 
7 BACKGROUND INFORMATION  ........................................................................................... 20 
7.1 Chronic Rhinosinusitis, Treatment Options and Unmet Clinical Need  ............................ 20 
7.2 Investigational Device  ...................................................................................................... 21 
7.3 Summary of  Preclinical Testing  ........................................................................................ 22 
7.4 Summary of Prior Clinical Experience  ............................................................................. 23 
8 STUDY OBJECTIVE  .................................................................................................................. 24 
9 STUDY DESIGN AND ENDPOINTS  ........................................................................................ 24 
9.1 Study Design  ..................................................................................................................... 24 
9.2 Study Endpoints  ................................................................................................................ 24 
10 SUBJE CT SELECTION AND WIT HDRAWAL  ..................................................................... 26 
10.1  Study Population  ............................................................................................................... 26 
10.2  Eligibility Criteria  ............................................................................................................. 26 
10.3  Subject Withdrawal  ........................................................................................................... 27 
11 SUBJECT TREATMENT AND STUDY PROCEDURES  ...................................................... 28 
11.1  Screening Phase  ................................................................................................................ 28 
11.2  Baseline/Procedure Phase  ................................................................................................. 29 
11.3  Follow -Up Phase  ............................................................................................................... 32 
12 CONCO MITANT MEDICATION ............................................................................................ 33 
13 MEDICAL AND SURGICAL  INTERVENTIONS  .................................................................. 34 
13.1  Medical Intervention  ......................................................................................................... 34 
13.2  Surgical Intervention  ......................................................................................................... 35 
14 ASSESSMENT OF SAFETY  ...................................................................................................... 35 
14.1  Specifications of Safety Parameters  .................................................................................. 35 
14.2  Classification of Adverse Events ...................................................................................... 36 
14.3  Guidelines for Reporting of Adverse Events  .................................................................... 36 
15 RISK/BENEFIT ASSESSM ENT  ................................................................................................ 37 
15.1  Potential Risks  .................................................................................................................. 37 
15.2  Minimization of Potential Risks  ....................................................................................... 39 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  6 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
15.3  Potential Risks to Study Subject Confidentiality  .............................................................. 39 
15.4  Potential Benefits from Study Participation  ..................................................................... 40 
15.5  Risk/Benefit Conclusion  ................................................................................................... 40 
16 STATISTICAL CONSIDERATIONS  ....................................................................................... 40 
16.1  Randomization Scheme  .................................................................................................... 40 
16.2  Sample Size Calculation  ................................................................................................... 40 
16.3  Analysis of Primary Endpoints  ......................................................................................... 41 
16.4  Analysis of Secondary Endpoints  ..................................................................................... 42 
16.5  Analysis of Safety Measures ............................................................................................. 42 
16.6  Handling Steroid or Surgical Interventions  ...................................................................... 42 
16.7  Sensitivity Analysis for the Primary Efficacy Endpoints ................................................. 42 
16.8  Analysis Populations  ......................................................................................................... 43 
17 STUDY MANAGEMENT  ........................................................................................................... 43 
17.1  Ethical Considerations  ...................................................................................................... 43 
17.2  Sponsor Responsibilities  ................................................................................................... 44 
17.3  Blinding  ............................................................................................................................ 46 
17.4  Investigator Responsibilities  ............................................................................................. 47 
17.5  Protection of Subject Confidentiality  ................................................................................ 49 
17.6  Study Suspension or Early Termination  ........................................................................... 49 
17.7  Site Closeout  ..................................................................................................................... 50 
17.8  Quality Assurance and Supervision by Authorities  .......................................................... 50 
17.9  Final Clinical Study Report  .............................................................................................. 51 
17.10  Publication Policy  ............................................................................................................. 51 
18 APPENDIX 1: LIST OF CORTICOSTERO ID MEDICATIONS  .......................................... 52 
19 REFERENCES  ............................................................................................................................. 53 
 
LIST OF FIGURES  
Figure 1: Schematic of the UP Device ........................................................................................................ 21 
Figure 2: Schematic of the UP Balloon Catheter  ........................................................................................ 22 
 
  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  7 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
2 LIST OF ABBREVIATIONS   
Abbreviations  Expansion  
ADE  adverse device effect  
AE adverse event  
AERD  aspirin exa cerbated respiratory di sease  
ARS acute rhino sinusitis  
ASADE  anticipated serious adverse device effect  
BSD  balloon sinus dilation  
CFR  Code of Federal Regulations  
CI confidence interval  
COPD  chronic obstructive pulmonary disease  
CRA  clinical research associate  
CRF  case report f orm 
CRS chronic rhino sinusitis  
CSF cerebrospinal fluid  
CSR  clinical study report  
CT computed tomography  
EDC  electronic data capture  
e.g. ‘exempli gratia’ in Latin, meaning ‘for example’  
ESS endoscopic sinus surgery  
et al ‘et alia’ in Latin, meaning ‘and others’  
FDA  Food and Drug Administration  
FSO frontal sinus ostium/ostia  
GCP  good clinical practice  
HIV human immunodeficiency  virus 
ICF informed consent form  
ICH International Council on Harmonisation  
i.e. ‘id est’ in Latin, meaning ‘that is’  
IFU instructions for use  
INCS intranasal cortico steroids  
IRB institutional review board  
ITT intent -to-treat 
IUD intrauterine device  
IV intravenous  
LLOQ  lower limit of quantification  
MF mometasone furoate  
PTE per-treatment -evaluable  
RESS  repeat endoscopic sinus surgery  
SAE  serious adverse event  
SADE  serious adverse device effect  
SNOT -22 Sino-Nasal Outcome Test 
UADE  unanticipated adverse device effect  
USADE  unanticipated serious adverse device effect  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  8 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
3 DEFINITIONS OF TERMS  
Term  Definition  
Adverse device effect (ADE)  Adverse event related to the use of an investigational medical device. This definition includes adverse events resulting from  insufficient or 
inadequate instructions for use,  deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device. This 
definition includes any event resulting from use error or from intentional 
misuse of the investigational medical device.  [BS EN ISO 14155]  
Adverse event (AE)  Any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings)  in 
subjects, users or other persons, whether or not related to the investigational medical device [ BS EN  ISO 14155]  
Adhesion /scarring  grading scale  
for the ethmoid sinus  Adhesion /scarring  severity in the ethmoid sinus graded on a 5 -point 
scale from 0 to 4 at the screening and baseline visits, as follows:  
0: None  
1:  Small but non -obstructing (no separation required)  
2: Obstructin g, but easily separated  
3:  Dense and obstructing, separation difficult  
4:  Severe: complete adhesion of the middle turbinate to the lateral nasal wall  
Adhesion/scarring grading scale for the FSO  Adhesion/scarring in the f rontal sinus ostium/o stia ( FSO) assessed on a 
4-point scale as follows:  
0:  No visible granulation/scarring in the FSO  
1:  Minimal amount of granulation, scarring or contraction            
observed but not obstructing the FSO (intervention not 
warranted)  
2:  Moderate amount of obstructive granulation, scarring or contraction present in the FSO (intervention is warranted)  
3: Significant amount of scarring or contraction causing obstruction of the FSO requiring intervention (likely to 
compromise patency if not r emoved)  
Acute rhinosinusitis (ARS)  Per the 2016 “International Consensus Statement on Allergy and 
Rhinolog y” definition, patient must have ≤ 4 weeks of symptomatic 
inflammation of the paranasal  sinuses and nasal cavity.  
Aspirin  exacerbated  respiratory 
disease  (AERD) Aspirin  exacer bated respiratory disease, also known as Samter’s Triad, 
is a chronic medical condition that consists of three clinical features: 
asthma, sinus disease with recurrent nasal polyps, and sensitivity to 
aspirin  and ot her non- steroidal anti-inflammatory drugs.  
Case report form (CRF)  Standardized forms designed to capture study  data as required by the 
protocol.  
Chronic rhino sinusitis (CRS)  Per the 2016 “International Consensus Statement on Allergy and Rhinolog y” defini tion, patient must have  ≥ 12 weeks of:  
• Two or more of the following symptoms:  
o Nasal  discharge ( anterior/posterior ) 
o Nasal blockage/ obstruction /congestion  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  9 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Term  Definition  
o Reduction/loss of smell  
o Facial pressure/pain  
• And o ne or more of the following findings:  
o Evidence of inflammation on paranasal sinus 
examination or computed tomography  
o Evidence of purulence coming from paranasal sinuses 
or ostiomeatal complex  
Device malfunction  Investigation al device: Failure to perform in accordance with its intended 
purpose when used i n accordance with the instruction s for use or clinical 
investigation plan. [BS EN ISO 14155]  
Compatible accessor y devices : Failure to meet its performance 
specifications or otherwise perform as intended. Performance specifications include all claims made in the labeling for the device. 
The intended performance of a device refers to the intended use for 
which the device is labeled or marketed. [21 CFR 803]  
Enrolled  Subjects are considered enrolled upon signing the informed consent 
form .  
Estimated FSO d iameter  Smallest and largest  diameters of the FSO are estimated endoscopically 
by probing with a 3- mm olive -shaped  frontal  sinus suction tip and 
reported in mm.  
Inflammation sc ore For the purpose of the endoscopic scoring method in this study, the term inflammation is a global descriptor defined to include mucosal 
edema, erythema hypertrophy and/or polypoid changes. The 
inflammation present in the frontal recess/FSO is estimated vis ually 
based on the endoscopic examination on a scale ranging from 0 ( no 
visible inflammation ) to 100 (severe inflammation ) involving extensive 
erythema, edema, or polyposis.  
Intent -to-treat population  Consist s of all subjects in whom a sinus dilation was attempted.  
An attempt occurs when the physician introduces the delivery system 
into the subject’s nostril with the intent of dilation.   
Patency grading scale for the FSO  Patency of the FSO assessed endoscopi cally by probing with a 3 -mm 
olive -shaped  frontal sinus suction  tip (“suction tip”) and graded on a 
5-point scale as follows:  
0:  Occluded (no opening visible ) 
1:   Significantly stenosed ( not occluded, but un able to pass the 
3-mm suction tip)  
2:   Moderately stenosed (able to easily pass the 3 -mm suction tip 
with no additional space around it)  
3:   Minimally stenosed (able to easily pass the 3 -mm suction tip 
with additional 1 -2 mm space around it)  
4:   Completely p atent (able to easily pass the  3-mm suction tip 
with additional >  2 mm space around it)  
Per-treatment -evaluable (PTE) 
population  Consists of all randomized patients who have received the assigned study 
device in the target sinus, who have no major procedural protocol 
deviations and for who m follow -up data are available.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  10 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Term  Definition  
Polyp grading scale  for the 
ethmoid sinus Polyps originating from the ethmoid sinus  assessed endoscopically and 
graded on an  8-point scale ranging from 0 to 4 as follows:  
0: No visible sinonasal polyps  
1: Small amount of sinonasal polyps confined in middle meatus  
1.5: Small amount of sinonasal polyps confined in middle meatus 
with expanded amount of polypoid edema obstructing ≥ 25% 
of the ethmoid sinus cavity  
2: Expanded amount of sinonasal polyps confined in middle meatus  
2.5: Expanded amount of sinonasal polyps confined in middle 
meatus with expanded amount of polypoid edema obstructing 
≥ 50% of the ethmoid sinus cavity 
3: Sinonasal polyps extending beyond middle meatus but not totally obstructing the nasal cavity  
3.5: Sinonasal polyps extending beyond middle meatus with 
expanded amount of polypoid edema obstructing ≥ 75% of the 
ethmoid sinus cavity  
4: Sinonasal polyps completely obstructing the nasal cavity  
Polypoid edema grading scale for 
the FSO  Polypoid edema in the frontal recess/FSO is assessed on a 4 -point scale as 
follows:  
0:   Normal mucosa, no visible p olyps /mucosal edema  
1:  Minimal amount of p olyps /mucosal edema 
2:   Moderate amount of polyps/polypoid edema  
3:  Expanded amount of polyps/ polypoi d edema  
Safety population  Consist s of all subjects exposed to investigational device with successful 
dilation of at least one  FSO 
Serious adverse event (SAE) Adverse events are considered “serious” if, in the view of either the 
investigator or sponsor, they result in any the follow ing outcomes:  
• Death; or  
• A life -threatening illness or injury ; or 
• Permanent impairment of a body structure or a body function; 
or 
• Inpatient hospitalization or prolongation of existing 
hospitalization; or  
• Medical or surgical intervention to prevent life -threatening 
illness  or injury or permanent impairment to a body structure 
or a body function ; or  
• Fetal distress, fetal death, or a congenital anomaly/birth defect . 
Important medical events that may not result in death, be life -threatening, 
or require hospitalization  may be considered serious when, based upon 
appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention  to prevent one of the outcomes 
listed in this definition. [BS EN ISO 14155 ] 
Serious adverse device effect  
(SADE) Adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  Anticipated serious adverse 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  11 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Term  Definition  
device effect (ASADE) is an effect which by its nature, incidence, 
severity or outcome has been identified in the risk analysis report.  
Sino -Nasal Outcome Test  
(SNOT -22) Validated, disease -specific, symptom -scoring instrument consisting of 
22 questions, each scored by patient on a 6 -point scale as follows:  
0: No problem   
1:  Very mild problem   
2:  Mild or slight problem   
3:  Moderate problem   
4:   Severe problem   
5: Probl em as bad as it can be  
The maximum total score for all symptoms is equal to  110. 
Source data All information in original records and certified copies of original records 
of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  
Source documents  Original documents, data , and records. Printed, optical,  or electronic 
document s containing source data.  
Subject  An individual who participates in a clinical investigation.  
Successful dilation  of the FSO Insertion of the UP  Device into the targeted FSO followed by 2 
consecutive complete inflations of the  balloon . 
Unanticipated adverse device 
effect (UADE)  Any serious adverse effect on health or safety or any life -threatening 
problem or  death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan or application, or any other 
unanticipated serious problem  associated with a device that relates to the 
rights, safety, or welfare of subjects.  [21 CFR 812]  
Unanticipated serious adverse 
device effect  (USADE)  Any serious adverse device effect which by its nature, incidence, severity 
or outcome has not been identified in the current version of the risk analysis report. [ BS EN ISO 14155; 21 CFR 812]  
Use err or Act or omission of an act that results in a different medical device 
response than intended by the manufacturer or expected by the user  
NOTE: Use error includes slips, lapses, and mistakes. An unexpected 
physiological response of the subject does not in  itself constitute a use 
error. [BS EN ISO 14155]  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  12 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
4 PROTOCOL SUMMARY 
Study Title  The ASCEND Study: A Clinical Evaluation of the UP  Drug-Coated  
Device in Patients with Chronic Rhinosinusitis   
Objective  To assess the safety, performance, and efficacy of the UP Drug -Coated  
Device when used  in chronic rhinosinusitis (CRS) patients undergoing 
balloon dilation of  frontal sinus ostia (FSO)  
Investigational Device  UP Drug -Coated  Device (mometasone furoate, 3000 mcg)  and UP 
Control  Device (together referred  to as “UP Device”) are balloon dilation 
devices intended to dilate the peripheral sinus ostia.  
The UP Drug -Coated  Device is intended to dilate and locally deliver 
steroids to the frontal  sinus ostia to maintain patency  in patients ≥  18 
years of age.  
Study Design  Prospective, multicenter, clinical trial enrolling  and treating a total of 75 
subjects in two cohorts:  
• PK c ohort  (N=5): A non -randomized cohort  to assess the systemic 
safety and performance of the UP  Drug -Coated  Device  for in-office 
bilateral dilation of the FSO (2 inflations in each FSO for a total of 4 
inflations per device).  Subsequently, the UP  Drug -Coated  Device 
may be used to dilate any sphe noid or maxillary sinuses. 
• Randomized c ohort (N= 70): A randomized, intra -patient controlled, 
blinded cohort of 70 subjects  to assess the safety and efficacy of the 
UP Drug -Coated  Device used for in- office dilation of the FSO . The 
FSO randomized to the treatment (Treatment) will undergo dilation 
using the  UP Drug- Coated  Device (2 inflations  per device ) while the 
contralateral FSO (Control) will be dilated with a UP Control  Device  
(2 inflations  per device ). 
Subject Enrollment  PK c ohort : 5 subjects at up to 3 study center s. 
Randomized c ohort : 70 subjects at up to 15 study centers across the U.S.  
 The PK cohort will enroll first.  
Study Population  Patients ≥ 18 years of age with c hronic rhinosinusitis ( CRS ) who  had 
prior endoscopic sinus surgery (ESS) including ethmoidectomy and 
uncinectomy and are candidates for balloon dilation because they present 
with bilateral stenosis of the frontal recess/ FSO due to scarring or 
polypoid edema, confirmed on endoscopy .  
Eligibility Criteria  Key inclusion criteria:  
• Confirmed diagnosis of CRS per the 2016, “International Consensus 
Statement on Allergy and Rhinology” definition. Patient must  have 
≥ 12 weeks of:  
o Two or more of the following symptoms:  
 nasal discharge (anterior/posterior)  
 nasal blockage/obstruction/congestion  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  13 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
 reduction/loss sense of smell  
 Facial  pressure/pain  
o And one or more of the following findings:  
 Evidence of inflammation on paranasal sinus examination 
or computed tomography ( CT) 
 Evidence of purulence coming from paranasal sinuses or ostiomeatal complex  
• Bilateral disease in the  frontal sinuses (Lund -Mackay score ≥  1 on 
each side) on CT scan within 30 days prior to enrollment  in the PK 
cohort and prior to randomization in the randomized cohort.  
• Patient has bilateral obstruction of the frontal recess/ FSO due to 
scarring and/or pol ypoid edema confirmed on endoscopy  (patency 
grade of 0 or 1 for each FSO) . 
• Balloon dilation of the FSO judged to be  feasible ( use light -assisted 
or image -guided instrument  such as a frontal sinus seeker  tip to 
confirm access of each FSO ) and medically appropriate . 
• Patient has had p rior ESS (> 3 0 days  with a healed mucosa ) 
including bilateral ethmoidectomy (anterior or total) and 
uncinectomy for better visualization of the FSO. Note: No additional 
surgical interventions will be allowed at  baseline /proced ure. Dilation 
of the maxillary and/or sphenoid sinus can be performed with a 
commercially available sinus dilation device, if clinically necessary, 
prior to randomization in the randomized cohort . 
Key exclusion criteria:  
• Expanded amount of ethmoid polyp osis (grade > 2 PK cohort, grade 
≥ 2 randomized cohort )  
• Complications from prior ESS or balloon dilation procedure ( e.g., 
cerebrospinal fluid leak or injury to the skull base ) 
• History of  aspirin  exacerbated respir atory dis ease (AERD)  
• Patient is a current smo ker 
• History of allergy or intolerance to mometasone furoate  
• Oral-steroid dependent condition  
• Evidence of acute rhino sinusitis , invasive fungal sinusitis or another 
disease or condition expected to compromise survival or ability to 
complete assessments duri ng the 30 -day follow -up period in the PK 
cohort and during the 60- day follow -up period in the r andomized 
cohort  
• Use of parenteral and injected steroids (e.g., Kenalog) 30 days prior 
to the baseline procedure  
• Use of oral steroids, budesonide or other sinus  steroid 
irrigations/rinses  or drops , nebulized steroids administered nasally 
14 days prior to screening  in the PK cohort and prior to baseline in 
the randomized cohort  
Primary Endpoints  PK cohort : Successful dilation of attempted FSO  using the UP D rug-
Coated Device with no unanticipated serious adverse device effects 
(USADE)  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  14 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Randomized  cohort : Difference in the patency grade of the FSO  between 
treatment sides  at Day 30, as determined by an independent , blinded 
sinus surgeon based on the centralized video -endoscopy  review  
Secondary Endpoints  Endoscopic endpoints  in the FSO  by clinical investigators  at specified  
timepoints through Day 30 in the PK cohort and through Day 60 in the 
randomized cohort : 
• Estimated diameter, smallest and largest  (mm)  
• Frequency and grade of p atency ( 5-point categorical scale)  
• Inflammation ( 0-100 scale)  
• Frequency and severity of adhesion/scarring ( 4-point categorical 
scale)  
• Frequency and grade of polypoid edema ( 4-point categorical scale)  
• Need for and frequency of post -dilation interventions (e.g., medical, 
repeat dilation, surgical)  
Endoscopic endpoints  in the FSO  by independent reviewer  in the 
randomized cohort:  
• Estimated diameter, smallest and largest (mm)  at Day 14 and Day 30  
• Frequency and grade of patency at Day 14 and frequency of patency 
at Day 30 ( 5-point categorical scale)  
• Inflammation (0- 100 scale)  at Day 14 and Day 30 
• Frequency and severity of adhesion/scarring ( 4-point categorical 
scale)  at Day 14 and Day 30 
• Frequency and grade of polypoid edema ( 4-point categorical scale)  
at Day 14 and Day 30 
• Need for and frequency of post -dilation interventions (e.g., medical, 
repeat dilation, surgical)  at Day 14 and Day 30 
 
Patient -reported outcomes (PK cohort only):           
• Change from baseline to Day 14 and Day 30 in Sino- Nasal Outcome 
Test (SNOT -22) scores  
Safety Evaluation  PK cohort :  
• Measurement of plasma concentrations of MF and cortisol at 
baseline before the baseline procedure ( dilation ) and at 0.5, 1, 2, 4, 
and 24 hours after dilation , and again in the morning of Day s 3, 7, 
14 and 30  
o A validated bioanalytical method for human plasma MF with a 
lower limit of quantification (LLOQ) of 0.25 pg/mL  
o A validated bioanalytical method f or cortisol with a LLOQ of 
1.00 ng/mL  
• Measurement of urinary cortisol excretion  for 24 hours  prior to the 
baseline procedure and for 24 hours after the baseline procedure  
o A validated bioanalytical method for human urinary cortisol with a LLOQ  of 1.00 ng/mL  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  15 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
All adverse events reported by subjects between enrollment and Day 30 
(end of study) will be tabulated.  
Randomized cohort : All adverse events reported by subjects between 
enrollment and Day 60 (end of study) will be tabulated. 
Concomitant 
Medications  • Leading up to the baseline procedure, there is a 30- day restriction for 
use of parenteral and injected steroids (e.g., Kenalog).  
• Leading up to the baseline procedure, a 14- day restriction for use of 
oral steroids, budesonide or other sinus steroid irrigations/rinses 
or drops, nebulized steroids administered nasally.  
• After the baselin e procedure, subjects will be allowed in the PK 
cohort and required in the randomized cohort to use saline 
sprays/rinses /irrigations  starting from Day 2.  
• If infection is suspected at any time during the study, treatment with 
antibiotics will be permitted.  
• Use of  intranasal corticosteroid (INCS) sprays will be allowed 
starting after  Day 14 visit in the randomized cohort , if medically 
necessary , and not allowed throughout the 30- day follow -up 
duration in the PK cohort.  
• Use of  other corticosteroids (e.g., oral , parenteral, injections, 
budesonide or other sinus steroid irrigations/rinses or drops, breath 
powered steroid delivery  [e.g. XHANCE™ , fluticasone 
proprionate ], nebulized steroids administered nasally) will not be 
permitted during the study follow -up unle ss clinically necessary.  
• Use of  orally- inhaled steroids  for control of asthma will be 
permitted, if already on such medications.  
• Use of corticosteroid -eluting sinus implants  (PROPEL®, 
PROPEL® Mini, PROPEL® Contour, SINUVA® Sinus Implant) or 
other nasal packing and spacers  is prohibited 14 days prior to 
baseline and during the baseline procedure and through Day  30 in  
the PK cohort and through Day 60 in the r andomized cohort . 
• To the extent possible, subjects will be maintained on stable 
regimens of leukotriene inhibitors and/or immunotherapy  for 
allergies, if currently on such regimens.  
Follow -up PK cohor t: Each subject will return for 6 follow -up visits at Days 1  
(24 hr coll ection) , 3, 7, 14, 21 and 30. All blood draws during follow -up 
should occur in the morning.  
Randomized cohort:  Each subject will return for 5 follow -up visits at 
Days 7, 14, 21, 30 and 60. 
Subjects in both cohorts may come in for additional  unscheduled office 
visits  if necessary. Circumstances that may warrant additional visits 
include but are not limited to : worsening of sinus symptoms, and/or  
sinus -related adverse events requiring medical evaluation.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  16 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Duration of Study Period  For a given  subject  in the PK cohort : Approximately 32 days =  screening 
visit (1 day) + baseline/procedure  (1 day) + follow -up (30 days)   
For a given subject  in the r andomized cohort : Approximately 62 days = 
screening visit (1 day) + baseline/procedure (1 day) + foll ow-up (60 
days)  
Overall: A pproximately 8 months  = 6- month enrollment phase + 2- 
month follow -up. 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  17 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
5 STUDY FLOW DIAGRAM  
 
Day 7 (± 2 d)
 Enrollment /Screening
Medications
Study Population
CRS patients (≥ 18 yr) with bilateral 
frontal sinus disease confirmed on CT (LM 
score ≥ 1 on each side ) and bilateral 
stenosis of frontal sinus ostia confirmed 
on endoscopy  
Abbreviations : CT, computed tomography ; FSO, frontal sinus ostia ; LM, Lund -Mackay score ; SNOT -22, Sino -nasal Outcome Test 
Saline rinses  necessary 
starting Day 2
Intranasal corticosteroid 
sprays starting after Day 14 
visit, if clinically necessary  
Corticosteroids  (e.g oral , 
parenteral , injection , 
budesonide or other steroid 
irrigations /rinses /drops , 
breath powered steroid 
inhalers , steroid nebulizers 
administered nasally ) not 
allowed unless clinically 
necessary 
Corticosteroid -eluting 
implants  or other nasal 
packing and spacers 
prohibited
Antibiotics allowed if 
clinically necessary 
Day 7 (± 2 d) 
 Endoscopic grading
ENT
Endoscopic grading
(before balloon dilation )
Endoscopic grading
Day 14 (± 2 d)
Endoscopic grading and 
video -endoscopy review
Day 21 (± 2 d)
 Endoscopic grading
Day 30 (± 2 d)
Endoscopic grading and 
video -endoscopy reviewRandomize
 (Intra -patient 
control )
Treatment  Side 
(balloon dilation 
with Drug -Coated 
Device )Control Side
(balloon dilation 
with Control 
Device )Randomized Cohort
N=70 subjects
Day 14 (± 2 d)
Day 30 (± 3 d)
Day 1 
Bilateral balloon
 dilation with Drug -
Coated DevicePK Cohort
N=5 subjects
Prior to the baseline 
procedure :
No parental or injected 
steroids for ≥ 30 days
 
No oral steroids , 
budesonide or other steroid 
irrigations /rinses /drops , 
nebulized steroids , 
cortico stero id -eluting 
implants for ≥ 14 days
Day 21 (± 2 d)
Patient  
SNOT -22
(before balloon 
dilation )
SNOT -22
Blood draw
24 hr
PK assessment  
Blood draw 
Basel ine (pre-procedure ),
0.5 hr, 1 hr, 2 hr, 4 hr 
(after -procedure )
Blood draw
Blood draw
Blood draw
SNOT -22
PK Cohort
Medications
Saline rinses  allowed 
starting Day 2
Intranasal corticosteroid 
sprays not allowed  
Corticosteroids  (e.g oral , 
parenteral , injection , 
budesonide respules , 
rinses or drops , breath 
powered steroid inhalers , 
steroid nebulizers 
administered nasally ) not 
allowed unless clinically 
necessary
Repeat balloon dilation or 
ESS allowed if clinically 
necessary
Antibiotics allowed if 
clinically necessary 
Prior to the baseline 
procedure :
No parental or injected 
steroids for ≥ 30 days
No oral steroids , 
budesonide or other 
steroid irrigations /rinses /
sprays or drops , nebulized 
steroids for ≥ 14 days
Randomized Cohort
Endoscopic grading
ENT
Endoscopic grading 
(before balloon dilation )
* FSO diameter assessment 
before /after balloon 
dilation
Endoscopic grading 
Endoscopic grading
Endoscopic grading
Endoscopic grading
 Blood draw
Endoscopic grading
Day 60 (± 7 d)
Day 3 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  18 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
6 SCHEDULE OF ASSESSMENTS   
6.1 PK Cohort  
Assessment  
Screening  
Baseline/  
Procedure  
Day 1  
 Day 3  
 Day 7 
(±2 d) Day 14  
(±2 d)  Day 21  
(±2 d)  Day 30  
(±3 d)  
Informed consent  X        
Medical/surgical history  X        
CT scan  (≤ 30 days  prior to enrollment)  X        
Blood sample collection  (~11 ml)  Xa Xb Xb Xb Xb  Xb 
24-hour urine collection   Xc Xc      
In-office bilateral FSO dilation   X       
Endoscopic grading and recording  X Xd   X X X X 
Sino-Nasal Outcome Test (SNOT -22)   Xd    X  X 
Concomitant medications  X X X X X X X X 
Adverse event reporting  X X X X X X X X 
Urine pregnancy test (female subjects  of 
childbearing potential ) Xe,f Xe,f       
Documented birth control (female subjects)    X X X X X X 
Abbreviations: CT, computed tomography; d, days; FSO, frontal sinus ostium/ ostia;  min, minutes ; ml, milliliter.  
a. Blood draws to occur at baseline, before balloon dilation proc edure and again at Hour 0.5 (±5 min) , 1 (±5 min), 
2 (±10 min) , and 4 (±15 min) after the end of baseline procedure  
b. All blood draws should occur in the morning and at approximately the same time of the day during the follow -up 
visits . Day 1 blood draw to occur 24 hours (±3 hours)  after the baseline procedure. Day 3 blood draw to occur 72 
hours (±3 hours) after the baseline procedure 
c. Urine samples will be collected for a 24- hour duration prior to the baseline visit (pre-procedure) and for a 24- hour 
duration following the baseline procedure (post -procedure)  
d. All endoscopic assessments and SNOT -22 performed prior to the baseline procedure,  except for the FSO 
diameter, which  must  be performed before an d after the balloon dilation procedure .   
e. Female subjects with reproductive potential are required to undergo a urine pregnancy test at screening and prior 
to the baseline procedure.  
f. Female subjects are required to confirm their nursing status at screening  and baseline   
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  19 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
6.2 Randomized Cohort  
Assessment  
Screening  
Baseline/  
Procedure  
Day 7  
(±2 d) Day 14   
(±2 d) Day 21  
(±2 d) Day 30  
(±2 d) Day 60  
(±7 d) 
Informed consent  X       
Medical/surgical history  X       
CT scan  (≤ 30 days  prior to randomization )  X      
In-office bilateral FSO dilation   X      
Endoscopic grading and recording  X Xa X X X X X 
Video -endoscopy grading (independent 
reviewer)     X  X  
Concomitant medications  X X X X X X X 
Adverse events reporting  X X X X X X X 
Urine pregnancy test (female subjects  of 
childbearing potential)  Xb,c Xb,c      
Documented birth control (female subjects)    X X X X X 
Abbreviations: CT, computed tomography ; d, day; FSO, frontal sinus ostium/ostia . 
a All endoscopic assessments performed prior to baseline procedure.  
b  Female subjects with reproductive potential are required to undergo a urine pregnancy test at screening and prior to 
the baseline procedure.  
c Female subjects are required to confirm their nursing status at screening and baseline . 
 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  20 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
7 BACKGROUND INFORMATION  
7.1 Chronic Rhinosinusitis, Treatment Options and Unmet Clinical Need  
Chronic rhinosinusitis (CRS) is defind as sinonasal inflammation  persisting for more than 
12 weeks . Sinusitis  is one of the most prevalent chronic diseas es, affecting about 12% of the 
adult population (Blackwell 2014 ). It causes a significant burden to the society at large (Rudmik 
2014) , as well as to the patient in terms of economics  (Bhattacharyya 2011; Ca ulley 2015)  and 
quality of life  (Soler 2011) . The cardinal symptoms of CRS include nasal congestion, nasal 
drainage (mucopurulence draining anteriorly or posteriorly ), facial pain or  pressure , and de crease 
or loss of sense of smell ( Orlandi 2016) . Addressing the underlying causes of CRS  and 
controlling the symptoms caused by the inflammatory process ha ve been the focus of medical 
therapy. Medical management of CRS includes intranasal corticosteroids, supplemented with a 
combination of antihistamines, antibiotics and/or oral steroids  (Orlandi 2016) . Patients who fail 
to respond to medical therapy may be referred for endoscopic sinus surgery (ESS) to improve ventilation and mucociliary clearance through the natural ostia  (Fokkens 2012) .  
ESS has been dem onstrated to improve patient -reported symptoms and quality of life in select 
patients with CRS who have persistent symptoms despite appropriate medical therapy . Longer -
term success rates for primary ESS are as high as 98%  (Ramadan 1999; Senior 1998) . However, 
the surgical outcomes are compromised by incomplete surgery, postoperative inflammation and adhesions, and recurrence of polyposis , which often require meticu lous postoperative 
debridement and effective medical management (Bhattacharyya 2004 ; Senior 1998) . While ESS 
with traditional instrumentation has been effective at enlarg ing the ostia , balloon dilation is 
increasingly used as either a stand -alone procedure or  as part of a hybrid surgery with traditional 
methods  (Chaaban 2017; Svider 2017) . This is particularly true when treating the frontal sinus 
where stenosis of the neo -ostium is a common sequela.  
Fueled by the need for minimally invasive, mucosa -sparing techniques, a catheter -based 
approach was introduced to reduce mucosal trauma, prevent scarring, bleeding and associated sequelae. Balloon sinus dilation (BSD) is a minimally invasive sinus surgery procedure to mechanically dilate the obstructed sinus ostia by inflating the balloon in the target sinus ostia .  
BSD  displaces and compresses  mucosa and causes microfracture of the underlying 
circumferential bone, enlarging the sinus ostia  and improving drainage . Patients treated with 
BSD ha ve been shown to have faster recovery, have less postoperative pain , and require fewer 
debridements than those undergoing traditional ESS (Catalano and Payne 2009; Chandra 2016; 
Levine 2008) . 
The safety and effectiveness of BSD  in the paranasal sinuses ha ve been evaluated in s everal 
clinical studies in treatment of stenosed peripheral sinus es in CRS  patients  (Achar 2012; Bikhazi 
2014; Bolger 2007; Cutler 2013; Friedman 2008; Koskinen 2017; Kuhn 2008; Levine 2008; Plaza 2011; Weiss 2008) . While the device is low risk with no major intraoperative 
complications ( Koskinen 2017; Levine 2008 ), a known response to the dilation itself is periosteal 
mucosal edema and ostial narrowing post -dilation ( Bolger 2007) .  
Intersect ENT has developed the UP Drug -Coated  Device which is a drug coated sinus dilation 
device intended to dilate and locally deliver drug  to the treated sinus ostia in CRS patients .  The 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  21 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
device is coated  with 3000 mcg  of the corticosteroid (MF) , to help minimize 
edema/inflammation following the sinus dilation procedure.  
7.2 Investigational  Device   
Intended use  
The UP Drug -Coated  Device is intended to dilate and locally deliver steroids  to the frontal  sinus 
ostia to maintain patency  in patients ≥  18 years of age.  
Device d escription  
The UP  Drug -Coated  Device and the UP Control Device  (hereafter referred to as “UP Device”) 
are over -the-wire sinus balloon catheter s with a  balloon at the distal e nd (with or without MF -
coating) . Figure 1  depicts a schematic representation of the UP  Device. On the proximal end of 
the device, there are two primary ports: the first port is compatible with an inflation device that is 
used to inflate the balloon with saline for sinus dilation ; and  the second  port is int ended to be 
used with a compatible lightwire and guide catheter to confirm access  into the target sinus. T he 
usable working length is 207 mm.  
 
 
Figure 1: Schematic of the UP  Device 
Balloon catheter  
The UP  balloon catheter is shown in Figure 2  and comprises  a nylon balloon and distal shaft 
with markers to denote balloon distance from the guide catheter. The s haft markers on the distal 
end of the catheter aid in proper placement. The yellow marker denotes the proximal end of the balloon and the white markers are space d 1 cm (single band) and 2 cm (double band) away from 
the proximal end of the balloon. The UP  Device has a s oft atraumatic distal tip. The balloon 
diameter is 6 mm in diameter  and t he 20 mm of  working length when inflated to a pressure of 12 
atmospheres (atm).  

 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  22 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
 
Figure 2: Schematic of the UP  Balloon Catheter  
Balloon c oating 
UP Drug -Coated Device: The  coating on  the balloon of the UP Drug -Coated  Device contains 
3000 mcg of  mometasone furoate ( the active ingredient)  in a polymer matrix of polyethylene 
glycol  and polysorbate (inactive ingredients). The  coating on the balloon is hydrophilic and 
designed to provide immediate release of MF  during dilation  into the apposing sinus mucosa .  
The device locally delivers  drug to the treated sinus ostia to reduce  edema/inflammation 
following sinus dilation .   
UP Control  Device: Similar to the UP Drug -Coated Device, t he UP Control Device is  an over -
the-wire sinus balloon catheter . The UP Control Device does not contain drug and is identical to 
the UP Drug -Coated Device with respect to dimensions of the balloon.  
No changes in the investigati onal device are anticipated during the study. An y changes in the 
investigational device during the conduct of the study will be documented and maintained by 
Intersect ENT .  
Compatible acces sory devices   
The UP Device is intended to be used with 0.035” comp atible lightwire  (e.g., Relieva Luma® 
Sentry Sinus Illumination System) , 70° sinus guide catheters  (e.g. R elieva  Flex ™ Sinus Guide 
Catheter Tip,  F-70 C ), compatible inflation device  (e.g., Acclarent ® SE  Inflation Device)  and 
the sinus g uide c atheter  handle (e.g., Relieva Sidekick Sinus Guide Catheter Handle (Low 
Profile) [Sidekick LP] ).  
7.3 Summary  of Pre clinical Testing  
Preclinical testing conducted on the investigational device included  bench studies  (mechanical 
and analytical) , simulated use testing in a  sinus model, shelf -life studies, biocompatibility,  
packaging  and sterilization studies . These studies  demonstrated that the investigational device 
meets its specifications  and the safety and performance requirements for use in humans . 

 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  23 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Additionally, Intersect ENT conducted a series of preclinical studies using the sheep  model  to 
ascertain preliminary safety and feasibility of delivering MF  to the sinus ostia. Plasma MF 
concentrations were maximum at 1 -hour post -dilation . The localized release of MF from the UP 
Drug-Coated  Device inflated once in both left and right FSO resulted in transient low systemic 
exposure to the drug. Systemic MF exposure peaked at 104 pg/mL (C max) by 1  hour (T max) but 
declined rapidly over 72 hours  to negligible or below L LOQ of  20 pg/mL  based on  assay s 
validated for sheep plasma.  
Sinus tissue MF exposure in animal studies  demonstrated that  tissue healing was not impaired  by 
the UP  Drug -Coated  Device. Based on visual assessment, no gross adverse ti ssue response s of 
edema or erythema and no clinical signs of infection were observed at any time point  through 
30 days  following dilation .  
7.4 Summary of Prior Clinical Experience  
The ASCEND study is the  first human study with the investigational device.  
The safety and efficacy of delivering MF locally to the sinus ostia via bioabsorbable implants 
have been extensively studied in several randomized controlled trials. The PROPEL® Family of 
Sinus Implants w as studied in 6 clinical trials  in the U.S., totaling over 350 patients. All 6 studies 
were designated as non -significant risk (NSR) studies . The PROPEL  Family of S inus Implants is  
coated with the same corticosteroid, MF,  and have demonstrated adequate safety . The PROPEL 
sinus implant is intended for use in patients ≥ 18 years of age following ethmoid sinus surgery to 
maintain patency, thereby reducing the need for post -operative intervention such as surgical 
adhesion lysis and/or use of oral steroids. The PRO PEL sinus implant separates mucosal tissues, 
provides stabilization of the middle turbinate, prevents obstruction by adhesions, and reduces 
edema. Since commercialization  of the PROPEL s inus i mplant  in 2011, the PROPEL  Family of 
Sinus Implants have been us ed in treatment of over 200,000 patients.  
In order to support the safety of the UP  Drug -Coated  Device with 3000 mcg of MF , a 
pharmacokinetic (PK) simulation was performed using published human plasma MF PK 
concentrations , following an intravenous  (IV) admi nistration of 400 mcg of MF and a simulated 
absorption process from the sinus following nasal administration of MF. Available human PK 
data for the approved MF products (specifically a dry -powder inhalation [DPI] administration of 
Asmanex®) and  supportive data from  MF plasma concentration -time profiles generated with the 
UP Drug -Coated  Device were used for comparison. Predicted AUC values with MF from the UP 
Drug -Coated  Device (459-1376 pg.hr/ml) were  similar to those reported for the approved daily 
doses of up to 880 mcg of MF administered as DPI and  metered dose inhalation  (MDI ) (93-1383 
pg.hr/ml) . Predicted C max ranges for the UP Drug -Coated  Device (105- 315 pg/ml) overlapped 
with the C max ranges reported for approved doses of DPI and MDI (35.2- 189 pg/ml) but were 
higher for those simulations which assumed a higher fraction of dose delivered (90%) or at higher (2%) bioavailability  than observed for approved products . The pred icted MF exposures 
(AUC and C
max) from the 3000 mcg  UP Drug -Coated  Device are comparable to observed MF 
exposures described in publicly available documentation at doses up to 1600 mcg/day ( Data  on 
file at Intersect ENT ). 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  24 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
8 STUDY OBJECTIVE  
To assess the safety, performance, and efficacy of the UP  Drug -Coated  Device when use d in 
CRS  patients undergoing balloon dilation of  FSO . 
9 STUDY DESIGN AND E NDPOINTS  
9.1 Study Design  
This is a prospective, multicenter  clinical trial des igned to evaluate the safety , performance,  and 
efficacy of the UP Drug -Coated  Device in CRS  patients who are candidates for  in-office balloon 
dilation  of the frontal recess/FSO .  
The trial consists of 2 cohorts:  
PK c ohort : A non- randomized cohort of  5 subjects  who are scheduled to undergo bilateral 
balloon dilation of the FSO. The UP Drug -Coated  Device will be us ed to perform balloon 
dilation  in the FSO (2 inflations in each FSO  for a total of 4 inflations per device).  
Randomized c ohort : A randomized, i ntra-patient control led, blinded cohort of  70 subjects  who 
are scheduled to undergo  bilateral  balloon dilation of the FSO . Subjects  will be randomized to 
undergo balloon dilation with the UP D rug-Coated  Device (2 inflations  per device) in one  FSO 
(Treatment) while the contralateral side will undergo balloon dilation  with the UP Control  
Device ( Control) .  
The PK cohort will enroll first. S ubject s in the PK cohort will be  followed for 30 days (± 3 d) 
post-procedure  and subjects in the r andomized cohor t will be followed for 60 days (± 7 d) post -
procedure .  
9.2 Study Endpoints  
9.2.1 Primary  Endpoint s  
PK c ohort : Successful  balloon dilation  of attempted FSO using the UP Drug -Coated  Device with 
no unanticipated serious adverse device effects (USADE) . Successful dilation is defined as 
insertion of the UP  Drug -Coated  Device into the targeted FSO followed by 2 consecutive 
complete inflations of the balloon.  
Randomized c ohort : Difference in  patency  grade of the FSO between treatment sides at Day 30 
as determined by an independent , blinded sinus surgeon based on the centralized, video-
endoscopy  review.  
• Patency of  the FSO is assessed endoscopically by probing with a 3 -mm olive -shaped 
frontal sinus suction tip  (“suction tip”) and graded on a 5- point scale . 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  25 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
9.2.2 Secondar y Endpoints  
Endoscopic m easures  in the F SO by clinical investigators at specified  timepoints through Da y 30 
in the PK cohort and through Day 60 in the r andomized cohort : 
• Estimated FSO diameter , smallest and largest  (mm) 
• Frequency and grade of p atency ( 5-point categorical scale)  
• Inflammation  (0-100 scale)  
• Frequency and severity of adhesion/scarring  (4-point categorical scale)  
• Frequency and grade of polypoid edema  (4-point categorical scale)  
Need for and frequency of post -dilation interventions ( e.g., medical, repeat dilation, 
surgical)  
Endoscopic endpoints  in the FSO  by independent reviewer in the randomized cohort:  
• Estimated diameter, smallest and largest (mm) at Day 14 and Day 30  
• Frequency and grade of patency at Day 14 and frequency of patency at Day 30 (5- point 
categorical scale)  
• Inflammation (0 -100 scale) at Day 14 and Day 30  
• Frequency and severity of adh esion/scarring (4 -point categorical scale) at Day 14 and Day 
30 
• Frequency and grade of polypoid edema (4- point categorical scale) at Day 14 and Day 30  
• Need for and frequency of post -dilation interventions (e.g., medical, repeat dilation, surgical) 
at Day 1 4 and Day 30  
Patient -reported outcomes (PK c ohort only):  
• Change from baseline  to Day 14 and Day 30 in Sino- Nasal Outcome Test (SNOT -22) 
scores  
See Section 3 Definitions of Terms . 
9.2.3 Safety Evaluation   
In the PK cohort , systemic s afety will be evaluated via m easurement s of plasma MF and cortisol 
concentrations and 24- hour urinary cortisol excretion. M orning  plasma MF and cortisol 
conc entrations before the baseline procedure  (dilation)  and at  0.5, 1, 2, 4, and 24 hours  after 
dilation , and again in the morning of Day  3, 7, 14 and 30 will be analyzed . The MF 
concentrations will be determined using a validated bioanalytical method a lower limit of 
quantification (LLOQ) of 0.25 pg/mL . Plasma cortisol will be determined using a validated 
bioanalytical me thod with a LLOQ of 1.00 ng/mL .  Measurement of urinary cortisol excretion  for 
24 hours  prior to the baseline procedure and for 24 hours after the baseline procedure will be 
analyzed  using a validated bioanalytical method with a LLOQ of 1.00 ng/mL.  
In both cohorts, a ll adverse events ( AE) reported by subjects between enrollment (i.e., consent 
date)  and the Day 30 follow -up visit in the PK cohort and the Day 60 follow -up visit in the 
randomized cohort (end of study)  will be tabulated . Each AE will be evaluat ed by clinical 
investigators  in terms of seriousness, severity (i.e., mild, moderate, severe) and strength of 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  26 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
relationship (i.e., not related, unlikely related, probably related, definitely related) to study drug, 
study investigational device,  study access ory device , and  dilation  procedure. 
Device malfunctions and use errors will be reportable as applicable for both the investigational 
and the accessory devices.    
10 SUBJECT SELECTION AND  WITHDRAWAL  
10.1 Study  Population  
The study population will consist of  patients ≥ 18 years of age with CRS who had prior ESS , 
including ethmoidectomy and uncinectomy , and are candidates for balloon dilation because they 
present with bilateral stenosis of the frontal recess/FSO due to scarring or polypoid edema, 
confirmed on e ndoscopy.  
10.2 Eligibility Criteria  
Subjects are eligible for treatment  (PK and randomized  cohort)  after they meet all of the 
following  inclusion criteria and none of the following exclusion criteria . 
Inclusion c riteria  
a. Patient has provided written informed consent using a form approved by the reviewing institutional review board ( IRB) and sponsor . 
b. Patient is ≥ 18 years of age.  
c. Patient is willing and able to comply with protocol requirements.  
d. Patient has a confirmed diagn osis of C RS, as defined in the 2016 “International Consensus 
Statement on Allergy and Rhinology” .  
e. Patient has  bilateral disease in the frontal sinuses ( Lund- Mackay score ≥  1 on each side) on 
CT scan within 30 days prior to enrollment  in the PK cohort and prior to randomization in 
the randomized cohort . 
f. Patient has had p rior ESS (> 3 0 days  with a healed mucosa) , including bilateral 
ethmoidectomy (anterior or total) and uncinectomy for better visualization of the FSO. Note : 
No additional surgical interventions will be allowed at baseline/ procedure . Dilation of the 
maxillary and/or sphenoid sinus can be performed with a commercially available sinus dilation device, if clinically necessary, prior to randomization in the randomized cohort. 
g. Patient is able to tolerate topical/local anesthesia.  
h. Female patients of reproductive potential must not be pregnant or nursing and must agree to 
not become pregnant during  their participation in the study.  
i. Female patients of childbearing  potentia l must agree to use consistent and acceptable 
method( s) of birth control during their participation in the study . 
j. Patient has bilateral obstruction of the frontal recess/ FSO due to scarring and/or polypoid 
edema confirmed on endoscopy  (patency grade of 0 or 1 for each FSO) . 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  27 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
k. Balloon dilation of the FSO with a 6 mm balloon is judged to be feasible ( use light -assisted 
or image -guided ins trument  such as a frontal sinus seeker  tip to confirm access of each FSO   
) and medically appropriate.  
Exclusion c riteria  
a. Patient has expanded amount of ethmoid polyposi s (grade > 2 in the PK cohort, and grade ≥ 
2 in the randomized cohort ). 
b. Complications from prior ESS or balloon dilation procedure ( e.g., cerebrospinal fluid leak or 
injury to the skull base ).  
c. History of  aspirin  exacerbated respir atory di sease (AERD) . 
d. Patient is a c urrent smoker . 
e. Patient has known history of allergy or intolerance to MF.  
f. Patient has used  parenteral or  injected steroids (e.g., Kenalog ) during 30 days prior to the 
baseline procedure .  
g. Patient  has clinical evidence of acute rhinosinusitis , as defined in the 2016 “International 
Consensus Statement on Allergy and Rhinology”.  
h. Patient has oral -steroid dependent condition such as chronic obstructive pulmonary disease 
(COPD) or asthma.  
i. Patient has u sed oral steroids, budesonide or other sinus steroid irrigations /rinses  or drops , 
nebulized steroids administered nasally during 14 days prior to the screening in the PK 
cohort and prior to baseline procedure in the randomized cohort  
j. Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on prior CT  scan, necrotic sinus tissue ). 
k. Patient has known history of human immunodeficiency virus (HIV) , immunoglobulin G or A 
subclass deficiency  or cystic fibrosis . 
l. Patient has evid ence of sever e concomitant disease or condition expected to compromise 
survival or ability to complete assessments during the 30- day study follow -up period in the 
PK cohort and during the 60- day study follow -up period in the r andomized cohort 
(e.g.,  cancer ). 
m. Patient is currently participating in another clinical study .  
n. Patient has known dehiscence of the lamina papyracea.  
o. Patient has evidence of  active tuberculosis or  active viral illness (e.g., ocular herpes simplex, 
chick enpox, and measles ). 
p. Patient has glaucoma (prior ocular exam with intraocular pressure of >  21 mm  Hg and 
pressure lowering medication given) or posterior subcapsular cataract.  
10.3 Subject Withdrawal  
Study subject may be withdrawn or terminated for the following reasons:  
• Subject de ath 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  28 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Concomitant disease or any pre -existing disease or condition that precludes subject’s 
participation.  
• Subject voluntarily chooses not to participate further in the study.  
• Subject ’s non- compliance with study proc edures . 
• Lost to follow -up: the subject has missed  a study visit and three documented attempts to 
contact the subject are unsuccessful. A subject who misses a study visit should be contacted 
by site personnel to determine the reason for the missed visit, which should be documented in the subject’ s study records. Note: A s ubject who misses a study visit but attends a subsequent 
visit will no longer be considered lost to follow -up. 
• In the clinical investigator ’s opinion, a si gnificant safety concern arises that requires subject 
discontinuation. 
• In the clinical investigator ’s opinion, it is not in the best interest of the subject to continue 
study pa rticipation.  
• In the sponsor’s or IRB’s opinion, it is not in the best interest of subject to continue the study.  
If a subject decides to withdraw from the study, clinical investigator should follow patient s with 
ongoing AEs till resolution  according to the standard of care. Data collected up to the point of 
subject withdrawal or termination will be maintained in the s tudy database and included in 
analyses as appropriate.  
All enrolled subjects , including those withdrawn or lost to follow -up, will be accounted for and 
documented.  
11 SUBJECT TREATMENT AND  STUDY PROCEDURES   
11.1 Screening P hase   
Pre-screening  
During the pre -screening phase,  clinical investigators  or designee s will perform an initial 
evaluation of potential candidates for study eligibility. This initial pre -screening phase may 
include review of existing patient information (e.g., previously performed diagnostic measures, medical history, sinus endoscopies, sinus surgery ).  
Consent, enrollment , and screening  
If the patient appears to be a potential candidate for the study based upon existing information, 
written informed consent will be obtained. No protocol  required testing will be performed solely 
for the purposes of this study prior to obtaining patient written informed consent.  
Clinica l investigators  or designee s will approach the patient to obtain written informed consent. 
The background of the proposed study, the dilation  procedure, the follow -up schedule and all 
potential risks and benefits will be carefully explained to each  patient. The  clinical investigator  
or designee obtaining the informed consent shall:  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  29 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Avoid any coercion of or undue influence of  patients to participate , 
• Not waive or appear to waive patient’s legal rights , 
• Use language that is non -technical and understandable to the patient , and  
• Provide ample time for the patient to consider participation . 
Each patient must sign and date the informed consent form (ICF) approved by an appropriate 
Institutional R eview Board (IRB)  and the sponsor . Patients are considered enrolled in the study 
upon signing the IRB -approved ICF. Enrolled subjects will be assigne d unique identifying codes 
by the  Electronic Data Capture (EDC) system and entered into the study database.  Upon 
enrollment, subjects will have a screening assessment.  
The screening assessment  for both cohorts  will include : 
• CT scan ( must be performed within 30 days prior to enrollment  in the PK cohort and 
prior to randomization in the r andomized cohort ),  
• Endoscopic examination, grading and video recording,  
• Female subjects  of reproductive potential must  confirm their nursing status , undergo a 
urine pregnancy  test, and be informed about acceptable birth control methods  as part of 
the screening assessment and again at baseline.  
PK cohort subjects  who pass the screening assessment will be asked to collect urine samples for 
a 24-hour duration prior to the baseline visit .  
For the r andomized cohort subjects, i f the screening visit occurs on the same day as the 
baseline/procedure visit, all assessments will be recorded in the baseline visit forms.  See Section 
5 Study Flow Diagram  and Section  6 Schedule of Assessments . All subjects who do not pass 
the screening assessment , including inability to confirm access to each FSO, will be considered 
as screen failures and will be terminated from the study. The reason for ineligibility will be 
recorded  in the EDC  system .  
11.2 Baseline /Procedure Phase  
Baseline assessment  
Upon meeting eligibility requirements, subjects in both cohorts will undergo a  baseline 
endoscopic examination , including  grading and video recording .  
Female subjects of childbearing potential will undergo a urine pregnancy test prior to the 
baseline procedure and be required to use acceptable contraceptive  method(s) during the entire 
durati on of the study follow -up. Acceptable methods of contraception may include : 
Established use of oral, injection or implantable  hormonal contraceptives ;  
• Double -barrier methods (i.e., intra -uterine devices) and b arrier contraceptives  (i.e., 
condom, diaphragm  or cervical/vault caps) used with spermicide ( foam, gel, film, cream 
or suppository );  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  30 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Female sterilization (e .g., tubal occlusion, hysterectomy or bilateral salpingectomy) ; or 
• Vasectomized male partner, if the sole partner for the subject.  
Note: The baseline endoscopic assessment  and pregnancy testing must be performed before the 
dilation  procedure . 
PK cohort : Baseline assessment will also include:  
• SNOT -22 questionnaire.  
• A blood sample collection prior to the baseline procedure.  
• Instructio ns for u rine sample  collection through 24 hours after the baseline procedure  
o Urine collection s tarting with the void after the procedure through 24 hours on 
following day.  
Subject preparation for baseline procedure  
Subjects will be prepared for the baselin e procedure per investigator’s standard protocol used for 
nasal endoscopy. The topical anesthesia regimen may consist of:  
• Spraying the nasal cavity with 4% lidocaine (or equivalent, such as pontocaine) with 
oxymetazoline (or equivalent) nasal decongestant spray;  
• Placing cotton pledgets soaked in lidocaine (or equivalent) and oxymetazoline (or equivalent) solution against the inferior turbinate, and into the ethmoid sinus (if available in the clinic setting, topical cocaine may be used); and  
• Injecting into the sinus tissue and/or polypoid tissue with lidocaine (or equivalent) as 
necessary.  
The anesthesia period should be as long as necessary to ensure complete numbness of the 
subject’s septum and middle turbinate. Once properly anesthe tized, subjects may unde rgo the 
baseline procedure.  
Baseline procedure  
All UP  Devices will be provided by  the study sponsor and must be used according to the 
instructions for use  (IFU) . Subjects will undergo bilateral in -office dilation of the FSO  with the 
study UP  Device.  
Prior to the baseline sinus dilation procedure , the FSO will be assessed under endoscopic 
visualization and the assessment will be recorded on the E ndoscopic S coring Form. Using a 3-
mm olive -shaped frontal sinus suction tip, the patency and FSO diameter as sessments will be 
performed. Final subject eligibility will be confirm ed based on bilateral stenosis  of the FSO  on 
endoscopic assessment.  NOTE: P hysician may use light- assisted or image -guided instrument 
such as a smaller diameter frontal sinus seeker  tip to confirm access of each FSO and if t he sinus 
is amenable to balloon insertion.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  31 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
No other devices, spacer , or packing (with or without  steroid ) may be used during  or after the 
baseline dilatio n procedure. Aggressive s uction and irrigations of the treated site should be 
avoided, as much as possible.  
In subjects in the PK cohort, dilation of the maxillary and/or sphenoid sinus with the same UP  
Device may be performed, if clinically necessary , after the index dilation procedure . In subjects 
in the r andomized cohort, dilation of the maxillary and/or sphenoid sinus with a commercially 
available balloon sinuplasty device may be performed, if clinically necessary , prior to 
randomization. No  other surgical procedures at baseline will be  allowed.  
The steps to be f ollowed for the in- office dilation procedure for this study  are as follows : 
1.  Insert a compatible light wire through the proximal end of the UP  Device.  
2. Insert the UP  Device into the compatible sinus guide catheter.  
a. If desired, attach the compatible sinus gui de catheter handle to the sinus guide 
cathete r before insertion of the UP  Device.  
3. Insert the sinus guide catheter into the FSO  and position the sinus guide catheter tip 
opening toward the FSO (See Section 7.2 Investigational Device  for compatible 
acces sory devices ). 
4. Confirm that the  lightwire is in the sinus, then a dvance the UP Device through the guide 
catheter and position it in the targeted FSO. Note: Under endoscopic visualization, ensure 
that the proximal end of the balloon (yellow single -band marker) is visible outside of the 
frontal sinus osti um. 
5. Inflate the balloon of the UP Device with the compatible inflation device to 12 
atmosphere s (atm ). 
6. Hold the inflated balloon at 12 atm  for a minimum of ~ 10 s and maximum of ~30 s. 
7. Deflate the balloon.  
8. Reposition the balloon distal  to the first  inflation  site such that the proximal half of the 
balloon is in contact  with sinus mucosa , adjacent to the first inflation site .  
9. Repeat steps 5 and  6 to dilate the sinus ostium  for a total of 2 inflations in each  sinus 
ostium. 
10. Retract the deflated balloon into the guide catheter before removing the di lation system 
out of the nostril  (Note: Do not  retract the tip of the UP  Device beyond the blue tip 
marker  on the guide catheter to prevent loss of the drug).  
PK cohort : Subjects will undergo in -office bilateral sinus dilation with the UP Drug -Coated  
Device in the frontal sinuses with 2 inflations per sinus (total of 4 inflations per Device).  
• Repeat steps 1 through 10  for each FSO with the same UP Drug -Coated  Device.  Note: 
Dilation of the maxillary and/or sphenoid sinus with the same UP  Device may be 
performed , if clinically necessary. However, dilation of the maxillary and/or sphenoid 
sinuses must be performed only after dilation of the frontal sinuses.  
• On the day of the baseline procedure, 4 additional blood draws (~ 11 ml at each 
timepoint) will be performed at 0.5 (± 5 min) , 1 (± 5 min) , 2 (± 10 min) and 4 (± 15 min) 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  32 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
hours following the end of the baseline procedure, defined as removal of UP  Device from 
the nostril af ter successful dilation of both FSO in each subject .  
Randomized cohort : Subjects w ill undergo an in- office sinus dilation with the UP D rug-Coated  
Device of  the FSO  random ized to treatment ( 2 inflations per device) while the contralateral FSO 
will serve as control and undergo sinus  dilation with a UP Control  Device ( 2 inflations per 
device).  
• Steps 1 through 10 will be followed with each frontal side dilated with the  assigned UP 
Device.   
Postoperative care  
PK cohort subjects will be required to collect urine samples for 24 hours following the baseline 
procedure.  
After the baseline procedure, subjects in the PK cohort will be allowed  and subjects in the 
randomized cohort will be required to use saline sprays /rinses/irrigations  starting Day 2.  
PK cohort subjects will not be allowed to use INCS  sprays throughout the 30 day s follow -up 
duration. Randomized cohort subjects will be allowed to use INCS sprays starting after the 
scheduled Day 14 study visit, if medically necessary .    
Device disposal  
The investigational and compatible accessory devices  must  be disposed per standard institutional 
practices for biohazard waste.  If the UP  Device or other compatible accessory devices  are 
associated with a device- related AE, malfunction , or failure, all the components should be 
returned to the  sponsor  for evaluation, as much as  possible. For the return of biohazard product, 
the sponsor  must be contacted prior to product return for handling instructions. 
Device malfunction and use error  
All potential and suspected device malfunctions and use errors of the investigational device will 
be reported to and reviewed by the sponsor. A ny AEs associated with the investigational device 
and/or compatible accessory devices will be recorded in  the corresponding CRFs  in the EDC 
system . 
11.3 Follow -Up Phase  
The follow -up period begins immediately post -procedure (once the subject exits the clinic).  
PK c ohort  
Each subject will return for up to 6 follow -up visits (see Section 5 Study Flow Diagram  and 
Section 6 Schedule of Assessments ). 
• Day 1  (24 hours ±  3 hours after the baseline procedure)  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  33 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Day 3 ( 72 hours ±  3 hours after the baseline procedure)  
• Day 7 ± 2  days  
• Day 14  ± 2 days  
• Day 21  ± 2 days  
• Day 30 ± 3 days  
The protocol -required follow -up assessment s through Day 30 will consist of:  
• SNOT -22 questionnaire (at Days 14 and 30)  
• Endoscopic examination, grading and video recording (at Days 7, 14, 21 and 30)  
• Blood sam ple collection of 11 ml (at Days 1, 3, 7, 14, and 30)  
o All blood draws must occur in the morning and at approximately the same time of 
the day during the follow -up visits. 
Randomized c ohort  
Each subject will return for up to 5 follow -up visits for endoscopic grading and video recording 
(see Section 5 Study Flow Diagram  and Section 6 Schedule of Assessments ).  
• Day 7 ±  2 days  
• Day 14  ± 2 days  
• Day 21  ± 2 days  
• Day 30  ± 2 days  
• Day 60 ± 7 days  
Unscheduled visits  
Subjects may come in for additional unscheduled office visits if necessary. Circumstances that 
may wa rrant additional visits include  but are not limited to:  
• Worsening of sinus sy mptoms , and/or  
• Sinus-related adverse events requiring medical evaluation . 
The assessment at an unscheduled visit will consist of:  
• SNOT -22 questionnaire  (PK cohort only ), and,  
• Endoscopic examination, grading and video recording . 
12 CONCOMITANT MEDICATI ON 
The study standardized medication regimen will be as follows:  
• Leading up to the baseline procedure, there is  a 30 -day restriction for use of parenteral 
and injected steroids (e.g., Kenalog) . 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  34 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Leading u p to the baseline procedure, a 14 -day restriction for use of oral steroids, 
budesonide or other sinus steroid irrigations/rinses  or drops , and nebulized steroids 
administered nasally .  
• After the baseline procedure, subjects will be al lowed  in the PK cohort and required in 
the randomized cohort to use saline sprays/ rinses /irrigations  starting at Day 2.   
• If infection is suspected at any time during the study, treatment with antibiotics will be 
permitted.  
• Use of intranasal corticosteroid (INCS) sprays is  allowed starting after Day 14 visit in the 
randomized c ohort , if clinically  necessary , and not allowed throughout the 30- day follow -
up period in the PK c ohort. 
• Use of other  cortico steroids ( e.g., oral, parenteral, injections, budesonide or other sinus 
steroid irrigations/rinses or drops, breath powered  steroid  delivery  [e.g. XHANCE™, 
fluticasone proprionate]  nebulized steroids administered nasally) will not be pe rmitted 
during the study follow -up unless  clinically necessary (see Sect ion 13 Medical and 
Surgical Interventi ons). 
• If already on such medications, use of orally -inhaled steroids for control of asthma will 
be permitted.  
• Use of corticosteroid -eluting sinus implants (PROPEL®, PROPEL® Mini, PROPEL® 
Contour , SINUVA®) or other nasal packing and spacers is  prohibited 14 days prior to 
baseline, during the baseline procedure and through Day 30 in the  PK cohort and through 
Day 60 in the r andomized cohort . 
• To the extent possible, subjects will be maintained on stab le regimens of leukotriene 
inhibitors and/or immunotherapy (e.g., Montelukast, Zafirleukast, Zileuton) for allergies throughout the follow -up duration, if currently on such regimens.  
All sinus -related medications will be recorded in  the EDC  system  including their full brand/trade 
or generic names (whichever prescribed), dose, frequency, indication, start and end dates are coded using the World Health Organization drug d ictionary.  
13 MEDICAL AND SURGICAL INTERVENTIONS  
Subsections below describe the res cue treatments consisting of medical and surgical 
interventions that will be allowed during the study follow -up based upon subject’s symptomatic 
and endoscopic outcomes. 
13.1 Medical In tervention  
During study follow -up, INCS  sprays will be allowed starting afte r Day 14  visit, if clinically 
necessary,  for subjects in the r andomized c ohort and not allowed throughout the 30- day follow -
up period for subjects in the PK c ohort.  
Other cortico steroids (e.g., oral, parenteral, injection, budesonide or other sinus steroid 
irrigations, rinses or drops, nebulized steroids administered nasally) will not be permitted unless 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  35 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
there is  a clinically significant increase or persistence in frontal  sinus inflammation  occurs, 
coupled with subject complaint of sinusitis symptoms that c ause subject to request medical 
intervention.  
13.2 Surgical Intervention  
Surgical intervention (e.g., repeat balloon dilation  or sinus surgery , in-office polypectomy ) may 
be required in cases where a clinically significant increase or persistence in frontal  sinus 
inflammation  occurs, coupled with complaints of sinusitis symptoms that cause subject to prefer 
a surgical intervention (e.g. sinus surgery ).  
All oral steroid and surgical intervention will be noted on the concomitant medication and 
follow up CRFs (see Section 16.6 Handling Steroid or Surgical Interventions ).  
14 ASSESSMENT OF SAFETY  
14.1 Specifications of Safety Parameters  
Pharmacokinetic analyses  
Plasma concentrations of MF and cortisol  at specified time points  will be performed . Samples 
will be analyzed with a validated bioanalytical method for both human plasma MF with a lower 
limit of quantification (LLOQ) of 0.25 pg /mL and for cortisol with an LLOQ of 1.00 ng/mL. 
Additionally,  measurement of urinary cortisol excretion 24 hours  prior to the baseline procedure 
and 24 hours after the baseline procedure will be analyzed using a validated bioanalytical method with a LLOQ of 1.00 ng/mL.  
Adverse event assessment  
Adverse events  (AE) for each subject from the time the subject gives informed consent through 
Day 30 in the PK cohort and through Day 60 in the r andomized cohort  (end of study) will be 
recorded in the EDC  system  and monitored. Each AE will be evaluated by clinical investigators  
in terms of strength of relationship (i.e., not related, unlikely related, probably related , definitely 
related ) to study drug, study device, and dilation  procedure. Each AE will be reviewed by 
sponsor personnel or contractors. The study sponsor is responsible for ensuring that all AEs are appropriately recorded and, when applicable, reported to the government(s), ethics committee(s) and other study center s per applicable regulations.  
Subjects  with CRS experience a persisting set of symptoms associated with the disease and may 
continue to present with a wide range of symptoms during the recovery process after in- office 
balloon dilation. These may include symptoms such a s pain and discomfort, headache, decreased  
sense of smell, crusting, epistaxis, and other symptoms. Patients healing appropriately after in -
office procedure may suffer from acute infections and/or inflammatory exacerbations unrelated to the procedure due t o the natural course of their CRS. Therefore, clinical investigators  will 
evaluate the occurrence of AEs excluding usual post -operative recovery signs and symptoms 
experienced by study subjects, unless corroborated by objective findings and/or requiring specific medical or therapeutic interventions ( e.g., antibiotics, repeat ESS, etc. ). 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  36 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Note: The need for medical or surgical intervention in the FSO  post -dilation that is  captured on 
the endoscopic scoring CRF , will not be considered an AE. Likewise, other endoscopic findings 
such as adhesion/scarring, polyp formation and restenosis of the FSO will not be considered AE.  
14.2 Classification of Adverse Event s 
All adverse events will be reported from the time of consent through study exit.  T he relationship 
of all AEs  to the investigational device will be categorized into:  
• Definitely r elated : There is a clear -cut temporal association, and no other possible cause.  
• Probably  related:  There is a clear -cut temporal association, and a potential alternative 
etiology is not apparent.  
• Unlikely related:  The AE does not follow a reasonable temporal association; or causal 
relationship with the drug, device, or procedure involved in the research is unlikely but 
cannot be completely ruled out. 
• Not r elated: The AE is comp letely inde pendent of study product  administration, and/or 
evidence exists that the event is definitely  related to another etiology. There must be an 
alternative, definitive etio logy documented by the investigator.  
Any AE  that is determined by a participating invest igator to be related (definitely  related , 
probably  related ) to the study drug, investigational device, accessory device or dilation 
procedur e will be categorized as device- related.   
For device -related AE (anticipated or unexpected/ unanticipated), the sponsor  may request source 
documentation to confirm the relationship of the AE to the investigational or accessory device 
and may review such AE with an independent otolaryngologist , as needed .  
14.3 Guidelines for Reporting of Adverse Events  
All AEs , regardles s of seriousness or relationship to the investigational device and compatible 
accessory devices , will be recorded in the EDC  system  and will include event description, date 
of onset, investigator ’s assessment of severity, relationship to investigational de vice, and date  of 
resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed through end of the study . 
Any pre -existing medical condition that is present at the time of  screen ing will not be reported as 
an AE. The occurrence of diagnostic or elective surgical procedures for a pre- existing condition 
will not be recorded as an AE, unless the condition become more severe or re sults in an AE . 
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. The 
investigator should specify the date of onset, severity , action taken with respect to the 
investigational or accessory device, corrective treatment/ therapy given, additional investigations 
performed, outcome, and his/her opinion as to whether there is a reasonable possibility that the AE was caused by the investigational or accessory device.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  37 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
The i nvestigator should take appropriate measures to follow all AEs until resolution or until 
progression has been stabilized, or until study exit, to  ensure the safety of the subjects. If the AE 
continues beyond the last planned visit per protocol  and/or the subject withdraws from the study , 
clinical investigators  should follow t he subjects according to standard of care.  
If a subject decides to withdraw from the study, clinical investigator should follow patients with 
ongoing AEs till resolution according to the standard of care.  
All AEs  must be reported to the sponsor based on the following timeline:  
Type of Report  Reporting  Schedule  to the S ponsor  
Investigational or accessory 
device- related AE  Verbal or written report within 10 working 
days 
Patient death Verbal report within 24 hours followed by a 
written report within 2 working days  
SAE/ SADE/ UADE /USADE  Verbal report within 24 hours followed by a 
written report within 5 working days  
Device malfunctions, device deficiencies and use errors must be reported to the sponsor 
promptly.  
The investigator will report the above to the reviewing IRB per the IRB’s guidelines. The study 
sponsor will be responsible for reporting safety events to the FDA as required per 21 CFR 812.  
All SAEs (SAE/SADE/ UADE/ USADE) will be followed until satisfactory resolution; until th e 
investigator deems the event to be chronic or the adherence to be stable  or until the subject exits 
the study . Other supporting documentation of the event may be requested by the sponsor and 
should be provided as soon as possible.  
All device deficiencies including malfunctions, use errors, and inadequate labeling, will be 
reported  to appropriate regulatory bodies and Institutional Review Boards (IRBs)/Ethics 
Committees (ECs) as applicable . 
Each AE will be coded using the Medical Dictionary for Regulatory  Activities (MedDRA) and 
presented based on the system organ class and preferred term.  
15 RISK/BENEFIT ASSESSM ENT 
A risk/benefit analysis has been performed, and a summary of the results is provided below.  
15.1 Potential Risks  
Risks a ssociated with the use of the UP Drug -Coated  Device are anticipated to be similar to 
those experienced by patients who undergo balloon dilation of the sinuses with a non- drug 
coated balloon.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  38 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Consequently, the risks potentially associated with the use of the UP  Device may include but are 
not limited to the following:  
• Epistaxis  
• Cerebrospinal fluid leak  
• Pneumocephalus  
• Damage of the orbital wall or other ocular structures  
• Impaired or loss of vision 
• Impaired t earing  
• Periorbital cellulitis/edema  
• Infection  
• Facial /nasal  pain  
• Facial/nasal dis comfort  
• Headache  
Risks or side effects  associated with intranasal mometasone furoate are:  
• Nasal irritation  
• Hypersensitivity reaction  
• Intranasal bleeding (epistaxis)  
• Localized infection (bacterial, fungal, or viral) in the nose or pharynx  
• Nasal burning 
• Nasal dryness  
• Susceptibility to secondary infections  
• Glaucoma/elevation of intraocular pressure  
• Cataracts/change in lens opacities  
• Headache  
• Pharyngitis  
Risks associated with steroids in general are:  
• Alteration of the hypothalamic -pituitary -adrenal  axis includ ing growth suppression 
• Immun osuppression  
• Hypersensitivity reactions  
• Headache  
• Epistaxis  
• Coughing 
• Vomiting  
• Candidiasis  
• Glaucoma/elevation of intraocular pressure  
• Cataracts/change in lens opacities  
• Arthralgia  
• Myalgia  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  39 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Inhaled and intranasal MF  is generally well tolerated in clinical trials and any AE  are mild and 
generally of short duration with  similar incidence to placebo. The  proportion of patients 
discontinuing as a result of AEs  related to treatment is very low and generally <  2-5% in most  
trials  (Asmanex 2005; Dulera 2010; Nasonex 2005) .  
Intranasal glucocorticoids may occasionally cause local adverse effects, s uch as a mild sensation 
of nasal irritation, crusting, dryness , and usually minor epistaxis ; however , these are transient 
and do not worsen during long -term treatment. Local mycotic infections and septal perforations 
with prolonged use of nasal corticoster oids are extremely rare and have not been reported for 
mometasone furoate. These findings may be related to the more rapid clearance of the topical 
corticosteroid by the ciliated nasal epithelium (Kyrmizakis 2000; Van Cauwenberge 2005; Vogt 1979) .  
The MF and polyethlene glycol material constituting the balloon -coating  has been used 
extensively in the manufacture of the PROPEL  Family of S inus Implants . The polysorbate 
material consistuting the balloon -coating has extensive history of use in medical devices such as 
vascular drug -coated balloons. Either material  is not expected to present any new risks.  
Risks associated with blood sample collection may include fainting, redness, pain, bru ising, and 
swelling at the site of venipuncture .   
15.2 Minimization of Potential Risks  
Risks a ssociated with the  UP Device are minimized via: 
• The use of medical grade materials that have a long history of use and have been characterized and tested to assure biocompatibility  
• Pre-clinical evaluation including bench testing, analytical testing, and animal studies  
• IFU that detail appropriate device preparation and d ilation  
• Selection of investigators with adequate experience and qualifications in the treatment of CRS  
• Training of the investigators on proper use of the UP Device, the study protocol, 
investigator responsibilities, and human subjects ’ protection. Routine subject follow -up 
that includes direct endoscopic visualization of the dilated sinus and surrounding tissue . 
Additionally, risks will also be minimized by including clinical investigators  experienced in 
performing balloon dilation procedures and nasal endoscopy.  
15.3 Potential Risks to Study Subject  Confidentiality  
In all clinical studies, confidentiality of protected health information may be breached due to 
study -related activities beyond those of routine clinical care. This risk will be minimized by not 
collecting personally identifying information on electronic C RFs or other study -related 
documentation to be provided to the study sponsor. It is the sponsor’s policy to redact any 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  40 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
subject ’s personally identifying information from any documentation sent to Intersect ENT that 
inadvertently contains it.  
15.4 Potential Bene fits from Study Participation  
There may be no direct benefits from participating in the study. However, study patients will 
undergo an enhanced level of clinical scrutiny compared to routine clinical care for CRS , which 
may provide some indirect health benefits.  
Subject s who receive the UP D rug-Coated  Device may benefit from dilation and local delivery 
of the drug that is intended to reduce post -dilation  inflammation/edema . Subjects who receive 
UP Control  Device may benefit from dilation of sinuses. 
15.5 Risk/B enefit Conclusion  
Based upon the Risk assessment  performed by Intersect ENT, the  risk profile is considered 
appropriate and acceptable given the phase of development of the device.  Potential benefits 
associated with the  UP Device are expected to outweigh the identified potential risks to the 
patient.  
16 STATISTICAL  CONSIDERATIONS  
A formal  Statistical Analysis Plan will be prepared prior to the study database lock and formal 
data analysis  from the randomized study . Data collected from the PK and randomized co horts 
will be analyzed separately. Following is a summary of the intended analyses. 
16.1 Randomization Scheme  
Randomized cohort  
The ratio of left to right sinus assignments will be 1:1.  Eligible subjects  will be randomized to 
receive the UP D rug-Coated Device i n one FSO  (Treatment) while  the contralateral side will 
receive the UP Control  Device (Control) . Randomization will be stratified by site  and will be 
implemented using the envelope method. The randomization scheme will be generated by an 
independent biosta tistician.  
16.2 Sample Size Calculation  
PK c ohort  
The sample size for this cohort was selected without regard for statistical considerations . 
The sample of 5 treated subjects was deemed adequate to assess whether there will be any 
quantifiable systemic exposure  to mometasone furoate when delivered via this route of 
administration.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  41 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Randomized c ohort  
The sample size calculation is based on t he primary efficacy endpoint – the  difference in the  
patency grade  at Day 30 between the treatment and control sides , as determined by a  blinded, 
independent sinus s urgeon based on the centralized video- endoscopy  review .  
The relevant  null and alternative hypotheses are:  
H0: μ = 0  
H1: μ ≠ 0  
where μ is the mean difference in  the FSO paten cy grade at Day 30 between t reatment and  
control  sides . The  study will be considered successful if the re is a statis tically significant 
difference in mean patency  grade  in favor of the UP D rug-Coated Device.  
The s ample size for this cohort  is calculated based on the following assumptions:  
• Expect ed mean difference of 0.5 between the treatment and control sides  in patency grade  
• A standard deviation (SD) of 1.1 for side -to-side difference in the  mean patency grade  
• Target power  of ≥ 90% 
• Type I error rate: α = 0.05, 2- sided  
A mean difference of 0.5 between the treatment and control sides in the patency grade  is 
considered clinically meaningful .  Based on standard formulas for a 1- sided t-test, a  sample size 
of 53 subjects provides at least 90% power to detect a difference  of 0.5 in mean patency  grade . 
Assuming 25% subjects with non-evaluable data on one or both side s, an additional 17 subjects 
will be enrolled for a total of 70 subjects in the r andomized cohort .  
16.3 Analysis of P rimary  Endpoint s 
PK c ohort  
The primary efficacy endpoint is t he number of s uccessful balloon dilations , which will be 
reported with descriptive statistics. The left and right sides of each subject will be considered 
independent, and each subject  is expected to contribute up to 2 observations. The study wi ll be 
considered successf ul if ≥  80% of attempted FSO  are dilated successfully  with no USADE  
related to the investigation device . A successful  FSO dilation is one in which the physician  has 
inserted  the UP  Drug -Coated  Device into the  targeted FSO, followed by 2 consecutive, complete 
inflations of the balloon. 
Continuous data from t he plasma MF , plasma cortisol and 24- hour urinary cortisol 
concentrations will be expressed using descriptive statistics, including but not limited to, means, 
standard deviations, medians, ranges and, where appropriate, coefficient of variation (%).  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  42 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Randomized c ohort  
The primary efficacy endpoint is the  difference in the patency grade  between treatment sides  at 
Day 30 as determined by an independent , blinded sinus surgeon bas ed on the centralized  video-
endoscopy  review.  
The primary efficacy endpoint will be analyzed using the  paired t -test.  
16.4 Analysis of  Secondary Endpoints   
Endoscopic  and patient -reported outcome  measures  and change from baseline in th ese measures  
(PK cohort only) will be summarize d.  C ontinuous data will be expressed as  means, standard 
deviations , medians, ranges and, where appropriate, 95% confidence intervals (CI) for the mean 
assuming a normal distribution . The p aired t -test will be conducted to assess  side-to-side 
differences. Categorical data will be expressed as counts  and percentages  and, where 
appropriate , 95% CI . To compare the need for post -dilation medical or surgical interventions  
(paired binary outcomes) at each timepoint, McNemar’s test will be used . Analyses  will be 
presented for each time point.   
To support potential product labeling  claims , a subset of secondary endpoints will be identified 
and analyzed using appropriate methods for controlling for family -wise type -1 error rate.  This  
will be detailed in the  statistical analys is plan prior to database lock for the randomized cohort .  
16.5 Analysis of Safety Measures  
The incidence of AE s and SAEs – including  investigational device- related AEs, USAD E – will 
be tabulated for the PK ( through Day 30) and r andomized  cohorts ( through Day 60) separately.  
16.6 Handling Steroid or Surgical Interventions  
Use of clinically necessary cortico steroids (e.g., oral, parenteral, injection, budesonide or other 
sinus steroid irrigations /rinses  or drops, nebulized steroids administered nasally) or surgical 
intervention (including repeat balloon dilation for the FSO) during the study will be recorded and 
tabulated.  
16.7 Sensitivity Analysis f or the Primary Efficacy Endpoint s 
Since the primary efficacy endpoint in the randomized cohort is determined by an independent 
blinded sinus surgeon based on review of video- endoscopies taken at Day 30, interventions 
performed by clinical investigators prior to Day 30  can potentially confound the primary efficacy 
outcome. Therefore, a sensitivity an alysis will be performed to test the robustness of the efficacy 
conclusion to actual interventions given. In this analysis, data imputations will be performed as 
follows:  
• If prior to  Day 30, a clinical investigator indicates on the Endoscopic Scoring Form that 
either frontal recess/FSO required oral steroids or surgical intervention, and such  
intervention was actually given, then the grades given by the independent reviewer will 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  43 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
be replaced by the grades given by the clinical investigator at the visit preceding  such 
intervention. 
• If oral steroids were actually prescribed for reasons other than either frontal recess/FSO, 
then the grades given by the independent reviewer will be replaced by the grades given by the clinical investigator at the visit preceding c ommencement of oral steroids ( prior to 
Day 30).  
Additional sensitivity analysis may be performed  to assess the sensitivity of the primary efficacy 
conclusion to patterns of missing data. This will be detailed in the statistical analysis plan.   
16.8 Analysis Populations  
PK cohort : The PK population will consist of all subjects in the safety population with at least 
one non- missing and eligible plasma concentration value .  
Safety population will consist of all subjects  and sinuses exposed to investigational device with 
successful dilation of at least one FSO.  
Randomized cohort : All primary analyses will be conducted on the intent -to-treat population. 
Additional analyses may be  performed on the per -treatment -evaluable population. 
• Intent -to-Treat  (ITT) p opulation will consist of all subjects  and sinuses wh ere a sinus 
dilation was a ttempted. An attempt occurs when the physician  introduces the UP Device 
into the subject’ s nos tril with the intent of dilation . Subjects  and sinuses  will be analyzed 
according to  randomiz ation assignment.  
• Per-Treatment -Evaluable  (PTE) population will consist of all randomized patients and 
sinuses which have received the assigned study device  in the target sinus, who have no 
major procedural protocol deviations , and for whom follow -up data  are available. 
If a subject  decides to discontinue from the study , every attempt will be made to continue to 
collect the safety and efficacy data according to the protocol procedures.  
17 STUDY MANAGEMENT  
17.1 Ethical Considerations  
The rights, safety and well -being of subjects  shall be protected in accordance with the ethical 
principles based in the Declaration of Helsinki  and consistent with ISO14155, 21 CFR Parts 11, 
50, 54, 56, and 812 Good Clinical Practice, all IRB requirements and  all applicable local laws 
and requirements . All parties are responsible  for ethical conduct of the study in accordance with 
their respective roles in the investigation. The sponsor and the investigator(s) shall avoid improper influence or inducement of the study subject, monitor, the clinical investigator(s) or other parties participating in or contributing to the clinical investigation.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  44 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
17.2 Sponsor Responsibilities  
Intersect ENT, as the study sponsor, has the overall responsibility for the conduct of the study 
and will ensure that the study is conducted under the guidance of ICH Good Clinical Practice 
(E6), Clinical investigation of medical devices for h uman subjects – Good clinical practice 
(BS EN ISO  14155) and other applicable local and federal (e.g ., 21 CFR Parts 11, 50, 54, 56, 
and 812) regulations, including the archiving of essential documents. A list of the names, locations, and chairpersons of all IRBs (including actions taken by each IRB on the protocol) that have been or will be asked to review the protocol will be kept on file. Qualified p ersonnel 
who participate in the conduct of this clinical trial will be qualified by education and/o r 
experience and trained  to perform their tasks.  Intersect ENT will not use , in any capacity , the 
services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this clinical study.  
17.2.1 Training  
Sponsor  personnel or designee will provide all clinical investigators w ith training on use of the 
UP Device prior to their participation in the clinical study.  
The study center  staff involved will undergo site initiation and training which will include :  
• Study protocol  
• Consenting procedures  and Human Subjects P rotection  
• Instructions  for use  
• Investigator responsibilities, including reporting requirements  
• Monitoring and a uditing  
• CRF completion guidelines  
• EDC  system  
• Electronic r ecordkeeping  
• Endoscopic grading scales, recording and video uploading 
• Investigational device accountability procedures  
• Protection of subject  confidentiality  
New members of the investigation site team may be added from time to time at new or existing 
sites. New personnel should only start their assignment af ter receiving adequate training in the 
clinical investigation requirements and this training shall be documented. The names, initials, 
signatures, functions, and designated authorizations of new site personnel shall be documented.  
17.2.2 Protocol Deviation  
Any deviation from the requirements outlined i n this protocol will be considered a protocol 
deviation. A protocol deviation that may affect the scientific soundness of the protocol or the rights, safety, or welfare of the patients  should be reported to the sponsor and the Institutional 
Review Board  (IRB) or Ethics Committee  as soon as possible . Other deviations are those that 
occur in direct association with a specific study patient. These include, but are not limited to, deviations from the informed consent process, inclusion/exclusion criteria, protocol -specified 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  45 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
procedures and assessments, and investigational device handling and usage. All efforts should be 
made to avoid any protocol deviation. 
17.2.3 Monitor Responsibilities  
Study site monitoring will be performed by trained and qualified Clinical Research  Associates 
(CRAs) from  the sponsor  and contract CRAs who will be trained and qualified by the s ponsor . 
Study sites will be visited regularly to ensure that the study is conducted in compliance with 21 CFR Parts 11, 50, 54, 56, 812, ISO 14155, the study protocol and other applicable regulations. 
Study monitors will also ensure that the data reporte d in the EDC  system is consistent with the 
information found in the subject ’s medical records and source documents (source data 
verification). Monitoring will include assessment of the site’s overall progress, including but not limited to the site’s ability to keep accurate records and to report study related data, including AEs, to the study sponsor in a timely fashion. A detailed monitoring plan will be develop ed and 
maintained by the sponsor.  
17.2.4 Data Management Responsibilities  
Data management will be performed by  the sponsor . 
Electronic data c apture  
An EDC system  will be utilized to capture study data  and compliant with 21 CFR Part 11 and 
under the guidance of  ‘FDA Guidance for Industry: Computerized Syste ms Used in Clinical 
Investigations ’. The EDC will be validated and verified prior to use, and validation and 
verification and release documentation will be maintained  on file by the study sponsor. Data 
entry will be performed by site personnel after completing an appropriate training. Modifications to the EDC will be made if deemed necessary by the study sponsor.  
Data c leaning 
The database will be subject to initial inspection for omitted data, gross data inconsi stencies,  and 
deviations. Any deficiencies or deviations will be reviewed and any necessary action determined (e.g., data query, communication with the study center).  
Intermittent data review will be performed  and any discovered errors will be reported to the 
study site using the electronic query process (as necessary). The study site will be expected to review and complete the query. The data cleaning cycle will be repeated until all data are considered clean.  
Data back- up, confidentiality and security  
Incremental data back -up will be performed on a regular basis  by the EDC system vendor . 
All media will be stored in a secure location. Passwords will be issued to appropriate personnel 
to ensure confidentiality a nd protection of data.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  46 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
17.2.5 Investigational Device Accountability  
An appropriate number of the investigational devices , the UP Drug -Coated  Device and UP 
Control  Device, will be provided to the study sites. The sites maintain the investigational devices 
in a lo cked, secure location. Only clinical investigators  participating in the study will have access 
to the investigational device. Dispensing of investigational device will be documented by 
authorized personnel. Each batch of the investigational device will be assigned a serial/lot number for tracking purposes.   
Investigational devices  received by the clinical site will be log ged in by the site personnel on 
inventory logs and/or the EDC  system . Final reconciliation will be completed at each site before 
or during site closur e. Any unused inventory of the investigational device will be returned to  the 
sponsor  at the direction of the sponsor or at the close of the study. At the end of the study, 
overall study final device  reconciliation will be completed internally by the s ponsor . 
17.3 Blinding  
17.3.1 Randomization  
Randomization assignment will be  stratified by site, will follow a blocked scheme with blocks of 
varying sizes, and will be performed using  the envelope method. After subjects meet  the study 
entry criteria,  have been anesthetized, and final eligibility  confirmed, site per sonnel will open the 
assigned randomization envelope  for that particular subject .   
17.3.2 Blinding  
The treatment and control devices are randomly designated with a device code  (e.g.: Device C 
and Device D) and do not co ntain any identifying information regarding  the treatment or control 
device. The information inside  the randomization envelope  will indicate which frontal sinus side 
receives which device code (e.g.: C or D ). After the first side is treated with the assigned device, 
that device will be discarded before opening the device assigned to the contralateral side, so that no side -by-side comparison of the two devices is made by the clinic al investigators  or clinical 
staff.  
Hence, the following personnel will be  blinded to treatment  assignment:  
• Research coordinators at the site who  have various  responsibi lities in conducting the study  
including assisting in baseline dilation procedure, handling randomization assignment, 
main taining investigational product accountability records, and compl ete AE  reports .  
• Sponsor representatives who serve as a resource and provide guidance for clinical 
investigators and clinical staff on procedure with the investigational devices  or during pat ient 
follow -up.  
• Clinical Research Associates from Intersect ENT and its sub -contractors (as  needed) , who 
perform routine monitoring activities .  
• The independent reviewer who will grade the Day 14 and Day 30 videoendoscopies .  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  47 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
17.4 Investigator Responsibilities  
General responsibilities  
• Each  investigator is responsible for ensuring that an investigation is conducted per  the signed 
investigator statement ( Investigator Agreement/ Commitment) , the study protocol , and 
applicable regulations; for protecting the rights,  safety, and welfare of study subject s under 
the investigator’s care  and for the control of drugs /devices  under investigation.  
• The investigator shall assure the accuracy, completeness, legibility and timeliness of the data 
reported to the sponsor on the CRFs and in all required reports.   
• Each  investigator shall obtain informed consent of each patient to whom the treatment is 
admi nistered  in accordance with provisions of 21 CFR P art 50  and ISO14155.  
• Each  investigator  (designee)  is responsible for all applicable IRB requirements under 21 CFR 
Part 56  and ISO14155.  
• Each  investigator is  responsible for disclosure of financial obligati ons/conflict of interest to 
the sponsor  in accordance with provisions of 21 CFR Part 54. 
• The study will be conducted under 21 CFR 11, 50, 54, 56, 812 and ISO14155.  Investigators 
will be trained on their responsibilities.  
• To ensure proper execution of the study protocol, each investigator will identify a study coordinator (s) for this study. Working with and under the oversight of the principal 
investigator, the study coordinator (s) en sures that all study requirements are fulfilled .  
• Each  investigator will allow monitoring and auditing of their clinical investigation 
procedure(s) by the sponsor or designee.  
Control and disposition of the investigational device  
An investigator shall administer the investigational device only to subjects under the clinical 
investigator’s personal supervision. The investigator shall not supply the investigational device to any person not authorized to receive it. An investigator  (or designee)  is required to maintain 
adequate records of the disposition of the investigational devices , including dates, quantity, and 
use by subjects . All unopened unused devices  must be returned to the  sponsor. 
Maintenance of s tudy r ecords  
Each  investigator is required to prepare and maintain adequate and accurate case histories that 
record all observations and other data pertinent to the investigation on each subject  participating 
in the investigational plan (including information maintained electronically such as digital imaging)  per 21 CFR 812. The investigator will also mainta in original source documents from 
which study -related data are derived, which may include, but are not limited to:  
• Clinic progress notes recording patient’s medical history and medications  
• Medical charts with operative reports and condition of patient upon discharge  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  48 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Medical records regarding AEs, and investigational device  malfunctions and deficiencies , 
use errors  (as applicable) including treatment and clinical outcome  
• Results of diagnostic examinations  
• Imaging records such as x -rays, CT scans and video -endoscopies and associated report s 
(hard copy and digital copy of images, as applicable/ available)  
• Notes of phone calls and/or correspondence indicating study center ’s attempts to follow 
study patients at the required follow -up visits until their par ticipation in the study is 
complete or terminated  
• Records relating to subject  deaths (e.g., death certificate, autopsy report)  
• Print outs of source data generated by technical equipment (e.g., CT, endoscopy, MRIs) 
must be filed with the subject ’s records.  
• Video of endoscopic procedures (screening, baseline  and follow -up assessments).  
An investigator shall retain records required to be maintained for a period of two years following 
the date a marketing application is approved for the device for the indicatio n for which it is being 
investigated. If no application is to be filed, records shall be retained for two  years after the 
investigation is discontinued. To avoid error, the study site should contact the study sponsor 
prior to the destruction of study recor ds to ensure that they no longer need to be retained. In 
addition, the s ponsor  should be contacted if the investigator plans to leave the study center , so 
that arrangements can be made for the handling or transfer of study subjects study  records, or if 
the records are moved to be under the oversight of a different sponsor -approved investigator or 
to an off -site location.   
Required documents from study center s 
At a minimum, the following documents will be provided by the study center  to the study 
sponsor:  
• IRB study approval letter  
• IRB approved informed consent  
• Fully executed clinical trial agreement (CTA)  
• Investigator a greement/ commitment for the participating investigator(s)  
• Financial disclosure form for the participating investigator(s)  
• Curriculum vitae  (CV) for the participating investigator(s)  
• Current medical license for the participating investigator(s)  
• Principal investigator protocol acknowledgement form  
A site may not begin active enrollment of patients until the document ation  for the site principa l 
investigator has been provided to the sponsor , a site initiation visit has been performed , and the 
sponsor has provided written approval to begin enrollment . 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  49 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
17.5 Protection of Subject C onfidentiality  
In all clinical studies, confidentiality of protected health information may be breached due to 
study -related activities beyond those of routine clinical care. This risk will be minimized by not 
collecting personally identifying information on CRFs or othe r study related documentation to be 
provided to the study sponsor. It is the sponsor’s policy to redact any subject ’s personally 
identifying information from any documentation sent to the s ponsor  that inadvertently contains 
it. 
At all times throughout the clinical investigation, confidentiality will be observed by all parties 
involved. All data shall be secured against unauthorized access. Privacy and confidentiality of 
information about each subject  shall be preserved in the reports and in any publication. Each 
subject  participating in this study will be assigned a unique identifier. All database forms and 
source documents sent to the sponsor will be tracked, evaluated, and stored using only this unique identifier.  
Clinical investigator s will maintain confidential study subject  lists identifying all enrolled 
subject s. The clinical investigators  bear responsibility for keeping these lists  current and 
confidential. These lists  will not be provided to the study sponsor.  
Monitors and auditors  will have access to the study screening and enrollment log s and other 
personally identifying information of study subject s to ensure that data reported in the EDC  
corresponds to the person who signed the ICF and the information contained in the original source documents. Such personal identifying information may include, the subject ’s name, 
address, date of birth, gender, race , and medical record number.  
The subject ’s name, medical record number or address will not  be recorded in the monitor’s visit 
repor t or the database. Demographic data that may be recorded include age, race, and gender.  
Any source documents copied for monitoring purposes by the sponsor will be identified by using 
the assigned subject ’s unique identifier in an effort to protect subject  confidentiality. All 
personally identifiable information will be redacted from source documents. 
17.6 Study Suspension or E arly Termination  
The study can be discontinued at the discretion of the investigator or study  sponsor for reasons 
including the following : 
• Occurrence of AE  unknown to date in respect to their nature, severity, or duration, or the 
unexpected incidence of known AE 
• Obtaining new scientific knowledge that shows that the study is no longer valid or necessary  
• Insufficient recruitment of subject s 
• Investigational drug /device presents an unreasonable and significant risk to subject s (the 
sponsor may terminate the study immediately)  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  50 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
• Persistent non- compliance with the study protocol  
• Persistent non- compliance with the applicable ethics committee or regu latory 
requirements  
• Sponsor decision to terminate study 
If the study is discontinued or suspended prematurely, the sponsor shall promptly inf orm all 
clinical investigators  and study center s of the terminati on or suspension and the reason(s) for 
termination.  The IRB shall also be informed promptly and provided with the reason(s) for the 
termination or suspension by the sponsor or by the clinical investigator and/or investigation 
center s. Regulatory authorities and the subject’s  physicians may also  need to be informed, if 
deemed necessary.  
17.7 Site Closeout  
At the time of the site close -out visit, the monitor will have ensured all outstanding study 
documents are reconciled, the investigator’s files are accurate and complete, have reviewed record retenti on requirements with the investigator, made a final accounting of all study supplies, 
and ensured that all applicable requirements are met for the study (this visit will be conducted according to the study sponsor’s SOP for close -out visits). Any specific observations and actions 
made at this visit may be documented in a f inal report.  
17.8 Quality Assurance and Supervision by Authorities  
All documents and data shall be produced and maintained in such a way to assure control of 
documents and data to protect the s ubject ’s privacy as far as reasonably practicable. The sponsor 
and representatives of the FDA or other regulatory authorities are permitted to inspect the study documents (e.g., study protocol, CRFs, and original study -relevant medical records/files) as 
needed. All attempts will be made to preserve subject  confidentiality.  
The study center s are subject to audit by study sponsor personnel or designee for p rotocol 
adherence, accuracy of CRFs and compliance with applicable regulations. The sponsor will communi cate to the site s any patterns of non -compliance. The sponsor will work with the site s to 
determine any necessary corrective action, as applicable. The spons or will continue to monitor 
sites until compliance has been secured. If the site continues to displ ay non -compliance, more 
serious action may be t aken by the  sponsor. The study protocol, data -recording procedures, data 
handling and study reports are subject to an independent clinical Quality Assurance audit by sponsor , its designee, or health authoritie s. 
Approved i nformed c onsent  form : protection of s tudy subjects  
An IRB must review and approve an ICF specific to this study. The s ponsor  will provide an 
example ICF. The site, to meet specific requirements, may modify this example ICF; however, 
the ICF must contain all of the elements required by sponsor . IRB approved ICF and renewed 
approvals as appropriate will be maintained by the site for the duration of the study. The original, 
signed and dated ICF for each subject  should be maintained by the site for monitoring.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  51 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Subject s will be informed both verbally and in writing ( i.e., ICF) about the nature of the study, 
the anticipated risks and benefits involved and the discomfort to which they will be exposed. 
They will be instructed about their right to discontinue their participation at any time without prejudice or jeopardy to future medical care. They must confirm consent in writing prior to any screening procedures. A copy of the informed consent form will be provided to the subject . 
Institutional r eview board approval  
IRB approval of study protocol and ICF is required prior to st udy commencement under 21 CFR 
Part 56. A justification of the non- significant risk determination of the study and any supporting 
information, as necessary, will be provided to the IRB under 21 CFR 812.2(b) . Clinical 
investigator s must also obtain renewal o f IRB approval throughout the duration of the study. 
Clinical investigator s are responsible for fulfilling any conditions of approval imposed by the 
reviewing IRB, such as regular reporting, study timing, etc. Clinical investigator s will provide 
the study sponsor with copies of such approvals and reports.  
Other i nvestigator r eports  
Clinical investigator s are responsible for notifying the sponsor of the following : 
Type of Notification  Timeline  
Withdrawal of IRB Approval  Verbal report within 24 hours followe d by a 
written report within 5 working days  
Informed Consent NOT  Obtained  Verbal or written report within 24 hours of 
becoming aware  
Notifications must identify subjects using the unique study identifier to protect subject’s 
confidentiality.  
17.9 Final Clinical Study R eport  
A final clinical study report (CSR) will be prepared by the study sponsor and provided to the 
regulatory agency , as needed .  
17.10  Publication P olicy  
At the completion of the study, an abstract reporting the results will be prepared and may  be 
presented at scientific meeting(s). A manuscript may also be prepared for publication in a peer -
reviewed scientific journal.  Co-authorship will be granted to the national investigator and to 
principle investigators  from each study site  based on enrollm ent contribution.  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  52 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
 
18 APPENDIX 1 : LIST OF CORTICOSTERO ID MEDICATIONS  
Trade Name  
(alphabetic al order)  Generic Name  Route of Administration  
Budesonide  
Pulmicort Respules  Budesonide  Nasal (e.g., irrigations, rinses)  
Dexamethasone  Dexamethasone  Intramuscular  
Oral 
Decadron  
Dexamethasone  Dexamethasone  Intravenous  or oral  
Nasal irrigations/rinses  
Depo Medrol  
Medrol  
Medrol Dosepak  
Methylprednisolone  Methylprednisolone  
Methylprednisolone Acetate  Oral  
Parenteral routes (e.g., intra-
articular, intra -cervical)  
Fluticasone  Fluticasone Propionate  
Fluticasone Propionate  w/Salmeterol  Nasal irrigations  
Intranasal sprays  
Kenalog  Triamcinolone  
Triamcinolone Acetonide  Intramuscular  
Subcutaneous  
Submucosal  
Mometasone  Mometasone furoate Nasal irrigations  
Intranasal sprays  
Prednisone  Prednisone  Intramuscular  
Oral  
Note for CRAs, data managers, biostatisticians: The above table is for reference purposes only and not a 
comprehensive list. Any questionable cases should be reviewed individually.  
  
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  53 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
 
19 REFERENCES  
Achar P, Duvvi S, and Kumar BN. Endoscopic dilatation sinus surgery (FEDS) versus functional 
endoscopic sinus surgery (FESS) for treatment of chronic rhinosinusitis: a pilot study. Acta Otorhinolaryngol Ital. 2012; 32(5):314- 9. 
Asmanex , Asmanex Twisthaler 110 mcg, 220 mcg (mometasone furoate inhalation powder)  - 
Prescribing information, 2005. Kenilworth, NJ. 
Bhattacharyya N. Clinical outcomes after revision endoscopic sinus surgery. Arch Otolaryngol 
HNS. 2004; 130:975- 978. 
Bhattacharyya N , Orlandi RR, Grebner J, et al. Cost burden of chronic rhinosinusitis: A claims -
based study. Otolaryngol HNS. 2011; 144(3):440- 445. 
Bikhazi NB, Light J, Truitt T, et al. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: A prospec tive, multicenter, randomized, controlled trial with 1 -year follow -up. 
Am J Rhinol Allergy. 2014; 28:1- 8. 
Blackwell DL, Lucas JW, and Clarke TC. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10. 2014; 260:1- 161. 
Bolger W, Brown C, Church C, et al. Safety and outcomes of balloon catheter sinusotomy: A multicenter 24 -week analysis in 115 patients. Otolaryngol HNS. 2007; 137:10- 20. 
Catalano PJ, and Payne SC. Balloon dilation of the frontal recess in patients with chronic frontal 
sinusitis and advanced sinus disease: an initial report. Ann Otol Rhinol Laryngol. 2009; 118(2):107- 12. 
Caulley L, Thavorn K, Rudmik L, et al. Direct costs of adult chronic rhinosinusitis by using 4 
methods of estimation: Results of  the US Medical Expenditure Panel Survey. J Allergy Clin 
Immunol. 2015; 136(6):1517- 22. 
Chaaban MR, Baillargeon JG, Baillargeon G, et al. Use of balloon sinuplasty in patients with 
chronic rhinosinusitis in the United States. Int Forum Allergy Rhinol. 2017; 7(6):600- 608. 
Chandra RK, Kern RC, Cutler JL, et al. REMODEL larger cohort with long -term outcomes and 
meta -analysis of standalone balloon dilation studies. Laryngoscope. 2016; 126(1):44- 50. 
Cutler J, Bikhazi N, Light J, et al. Standalone balloon dil ation versus sinus surgery for chronic 
rhinosinusitis: a prospective, multicenter, randomized, controlled trial. Am J Rhinol Allergy. 2013; 27(5):416- 22. 
Dulera. Dulera® (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol, for oral in halation use -  Prescribing information. 2010. 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  54 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Fokkens W, Lund V, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 
2012. Rhinol Suppl. 2012; 23:1- 298. 
Friedman M, Schalch P, Lin HC, et al. Functional endoscopic dilatation of the s inuses: patient 
satisfaction, postoperative pain, and cost. Am J Rhinol. 2008; 22(2):204- 9. 
Koskinen A, Mattila P, Myller J, et al. Comparison of intra -operative characteristics and early 
post-operative outcomes between endoscopic sinus surgery and balloon sinuplasty. Acta 
Otolaryngol. 2017; 137(2):202- 206. 
Kuhn FA, Church CA, Goldberg AN, et al. Balloon catheter sinusotomy: one -year follow -up--
outcomes and role in functional endoscopic sinus surgery. Otolaryngol Head Neck Surg. 2008; 139(3 Suppl 3):S27- 37. 
Kyrmizakis DE, Papadakis CE, Lohuis PJ, et al. Acute candidiasis of the oro-  and hypopharynx 
as the result of topical intranasal steroids administration. Rhinology. 2000; 38(2):87- 9. 
Levine HL, Sertich AP, 2nd, Hoisington DR, et al. Multicenter registry of balloon catheter sinusotomy outcomes for 1,036 patients. Ann Otol Rhinol Laryngol. 2008; 117(4):263- 70. 
Nasonex. Nasonex® (mometasone furoate monohydrate) Nasal Spray - Prescribing Information. 
2005. 
Orlandi RR, Kingdom TT, Hwang PH, et al. International  Consensus Statement on Allergy and 
Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016; 6 Suppl 1:S22 -S209. 
Plaza G, Eisenberg G, Montojo J, et al. Balloon Dilation of the Frontal recess: A randomized 
Clinical Trial. Annals of Otology, Rhinology, & Laryngology. 2011; 120(8):511- 518. 
Ramadan HH. Surgical causes of failure in endoscopic sinus surgery. Laryngoscope. 1999; 109(1):27- 9. 
Rudmik L, Smith TL, Schlosser RJ, et al. Productivity costs in patients with refractory chronic rhinosinusitis. Laryngos cope. 2014; 124(9):2007- 12. 
Senior BA, Kennedy DW, Tanabodee J, et al. Long -term results of functional endoscopic sinus 
surgery. Laryngoscope. 1998; 108(2):151- 7. 
Soler ZM, Wittenberg E, Schlosser RJ, et al. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011; 121(12):2672- 8. 
Svider PF, Darlin S, Bobian M, et al. Evolving Trends in Sinus Surgery: What Is the Impact of Balloon Sinus Dilation? Laryngoscope. 2017.  
Van Cauwenberge P, Van Hoecke H, Vandenbulcke L, et a l. Glucocorticosteroids in allergic 
inflammation: Clinical benefits in allergic rhinitis, rhinosinusitis, and otitis media. Immunol Allergy Clin N Am. 2005; 25:489- 509. 
 
Clinical Study Protocol P500 -0118 (The ASCEND Study ) 
Doc# CP -00017 Rev. 8.0,  04 April 2019  
 
CONFIDENTIAL  55 of 55 
May not be reproduced outside of Intersect ENT without written permission from Document Control.  
Vogt F. The incidence of oral candidiasis with use of inhaled corticosteroids. Ann Alle rgy. 1979; 
43(4):205- 210. 
Weiss RL, Church CA, Kuhn FA, et al. Long -term outcome analysis of balloon catheter 
sinusotomy: two- year follow -up. Otolaryngol Head Neck Surg. 2008; 139(3 Suppl 3):S38- 46. 
 